BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sandborn WJ, Feagan BG, Marano C, Zhang H, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Colombel JF, Reinisch W. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85-95; quiz e14-15. [PMID: 23735746 DOI: 10.1053/j.gastro.2013.05.048] [Cited by in Crossref: 480] [Cited by in F6Publishing: 500] [Article Influence: 53.3] [Reference Citation Analysis]
Number Citing Articles
1 Shinn J, Lee J, Lee SA, Lee SJ, Choi AH, Kim JS, Kim SJ, Kim HJ, Lee C, Kim Y, Kim J, Choi J, Jung B, Kim T, Nam H, Kim H, Lee Y. Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease. Pharmaceutics 2022;14:1969. [PMID: 36145716 DOI: 10.3390/pharmaceutics14091969] [Reference Citation Analysis]
2 Iizuka M, Etou T, Sagara S. Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy. World J Gastroenterol 2022; 28(34): 4959-4972 [DOI: 10.3748/wjg.v28.i34.4959] [Reference Citation Analysis]
3 Zhang T, Zhang B, Tian W, Wang F, Zhang J, Ma X, Wei Y, Tang X. Research trends in ulcerative colitis: A bibliometric and visualized study from 2011 to 2021. Front Pharmacol 2022;13:951004. [DOI: 10.3389/fphar.2022.951004] [Reference Citation Analysis]
4 Kinoshita N, Kakimoto K, Shimizu H, Nishida K, Numa K, Kawasaki Y, Tawa H, Nakazawa K, Koshiba R, Hirata Y, Sakiyama N, Koubayashi E, Takeuchi T, Miyazaki T, Higuchi K, Nakamura S, Nishikawa H. Serum IL-13 Predicts Response to Golimumab in Bio-Naïve Ulcerative Colitis. JCM 2022;11:4952. [DOI: 10.3390/jcm11174952] [Reference Citation Analysis]
5 Odufalu F. Editorial: Racial Difference in Efficacy of Golimumab in Ulcerative Colitis. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izac179] [Reference Citation Analysis]
6 Ishida N, Tani S, Asai Y, Miyazu T, Tamura S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis. Sci Rep 2022;12:13572. [PMID: 35945329 DOI: 10.1038/s41598-022-17763-2] [Reference Citation Analysis]
7 Bouhnik Y, Atreya R, Casey D, Górecki M, Baik D, Yoon SW, Kwon TS, Jang M. Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment. Inflamm Bowel Dis 2022:izac160. [PMID: 35942647 DOI: 10.1093/ibd/izac160] [Reference Citation Analysis]
8 Crispino F, Grova M, Bruno EM, Monachino N, Rizzo G, Casà A, Renna S, Macaluso FS, Orlando A. Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets. Drugs 2022. [PMID: 35900700 DOI: 10.1007/s40265-022-01750-y] [Reference Citation Analysis]
9 Ishida N, Asai Y, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Lymphocyte-to-monocyte ratio is a short-term predictive marker of ulcerative colitis after induction of advanced therapy. Gastroenterol Rep (Oxf) 2022;10:goac025. [PMID: 35692303 DOI: 10.1093/gastro/goac025] [Reference Citation Analysis]
10 Hernandez Santana YE, Irwin N, Walsh PT. IL-36: a therapeutic target for ulcerative colitis? Expert Opin Ther Targets 2022;:1-6. [PMID: 35634891 DOI: 10.1080/14728222.2022.2084381] [Reference Citation Analysis]
11 Ferrante M, Schirbel A, Pierik MJ, Haas T, Flamant M, Khalifa A, Philip G, Cornillie F, Meehan AG, Govoni M. Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study. Eur J Gastroenterol Hepatol 2022;34:646-54. [PMID: 35412484 DOI: 10.1097/MEG.0000000000002374] [Reference Citation Analysis]
12 Schubert S, Picker N, Cavlar T, Knop J, Kahraman A, Mohl W. Inflammatory Bowel Disease Patients' Treatment Preferences Using a Discrete Choice Experiment Technique: The InPuT Study. Adv Ther 2022;39:2889-905. [PMID: 35451740 DOI: 10.1007/s12325-022-02143-z] [Reference Citation Analysis]
13 Pandey A, Achrafie L, Kodjamanova P, Tencer T, Kumar J. Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, economic and quality-of-life outcomes. Curr Med Res Opin 2022;:1-40. [PMID: 35608153 DOI: 10.1080/03007995.2022.2081453] [Reference Citation Analysis]
14 Taxonera C, Fernández-Aceñero MJ, Olivares D, Calvo M, Casis B, Bermejo F, López Serrano P, Iborra M, Mesonero F, Boscá Watts M, Díaz Del Arco C, Vera I, Olivares S, Algaba A, Alba C. Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitis. Aliment Pharmacol Ther 2022. [PMID: 35509152 DOI: 10.1111/apt.16964] [Reference Citation Analysis]
15 Aoun R, Hanauer S. A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2022;16:411-23. [PMID: 35400292 DOI: 10.1080/17474124.2022.2065258] [Reference Citation Analysis]
16 Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'haens G, Nakase H, Panés J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV, Sandborn WJ, Reinisch W, Chen M, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. The Lancet 2022. [DOI: 10.1016/s0140-6736(22)00581-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med 2022;11:2302. [PMID: 35566428 DOI: 10.3390/jcm11092302] [Reference Citation Analysis]
18 Juillerat P, Grueber MM, Ruetsch R, Santi G, Vuillèmoz M, Michetti P. Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100104] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Amano T, Shinzaki S, Asakura A, Tashiro T, Tani M, Otake Y, Yoshihara T, Iwatani S, Yamada T, Sakakibara Y, Osugi N, Ishii S, Egawa S, Araki M, Arimoto Y, Nakahara M, Murayama Y, Kobayashi I, Kinoshita K, Ogawa H, Hiyama S, Shibukawa N, Komori M, Okuda Y, Kizu T, Yoshii S, Tsujii Y, Hayashi Y, Inoue T, Iijima H, Takehara T. Elderly onset age is associated with low efficacy of first anti-tumor necrosis factor treatment in patients with inflammatory bowel disease. Sci Rep 2022;12:5324. [PMID: 35351986 DOI: 10.1038/s41598-022-09455-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Kishi M, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. J Gastroenterol 2022. [PMID: 35235037 DOI: 10.1007/s00535-022-01862-y] [Reference Citation Analysis]
21 Song L, Zhang Y, Zhu C, Ding X, Yang L, Yan H. Hydrogen-rich water partially alleviate inflammation, oxidative stress and intestinal flora dysbiosis in DSS-induced chronic ulcerative colitis mice. Adv Med Sci 2022;67:29-38. [PMID: 34784538 DOI: 10.1016/j.advms.2021.10.002] [Reference Citation Analysis]
22 Bonovas S, Pansieri C, Piovani D, Macaluso FS, Orlando A, Festa S, Papi C, Pugliese D, Armuzzi A. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology. Dig Liver Dis 2022:S1590-8658(22)00134-7. [PMID: 35183439 DOI: 10.1016/j.dld.2022.01.123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Louis E, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Dignass AU, Magro F, Márquez JR, Moschen AR, Narula N, Rydzewska G, Freddi MJ, Travis SP. Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterol 2022;9:e000853. [DOI: 10.1136/bmjgast-2021-000853] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Perrig K, Krupka N, Jordi SBU, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka SR, Juillerat P, Burri E, Zimmermann D, Maillard MH, Sulz MC, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therap Adv Gastroenterol 2022;15:175628482210741. [DOI: 10.1177/17562848221074188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Sieber A, Aberra FN, Bonhomme B, Mckeever L, Lewis JD. Influence of Corticosteroid Use on Short- and Long-Term Outcomes of Biologic Therapy for Inflammatory Bowel Diseases. Dig Dis Sci. [DOI: 10.1007/s10620-021-07361-z] [Reference Citation Analysis]
26 Cleveland NK, Torres J, Rubin DT. What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented? Gastroenterology 2022:S0016-5085(22)00077-4. [PMID: 35101421 DOI: 10.1053/j.gastro.2022.01.023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
27 Bhattacharya S, Cross RK. Medical treatment of ulcerative colitis. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100863] [Reference Citation Analysis]
28 Fukuchi T, Kawashima K, Koga H, Utsunomiya R, Sugiyama K, Shimazu K, Eguchi T, Ishihara S. Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Ma X, Xu H, Zhang D. Impact of biological agents and tofacitinib for moderate-to-severe ulcerative colitis on health-related quality of life: a protocol for a network meta-analysis. BMJ Open 2021;11:e055182. [DOI: 10.1136/bmjopen-2021-055182] [Reference Citation Analysis]
30 Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut 2021:gutjnl-2021-326390. [PMID: 34937767 DOI: 10.1136/gutjnl-2021-326390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
31 Qiu P, Liu L, Fang J, Zhang M, Wang H, Peng Y, Chen M, Liu J, Wang F, Zhao Q. Identification of Pharmacological Autophagy Regulators of Active Ulcerative Colitis. Front Pharmacol 2021;12:769718. [PMID: 34925026 DOI: 10.3389/fphar.2021.769718] [Reference Citation Analysis]
32 Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev 2021;:103017. [PMID: 34902606 DOI: 10.1016/j.autrev.2021.103017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Forbes A. Immunosuppressants and immune modulators in luminal gastroenterology. Best Pract Res Clin Gastroenterol 2021;54-55:101759. [PMID: 34874843 DOI: 10.1016/j.bpg.2021.101759] [Reference Citation Analysis]
34 Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00377-0. [PMID: 34856198 DOI: 10.1016/S2468-1253(21)00377-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
35 Bots SJ, Parker CE, Brandse JF, Löwenberg M, Feagan BG, Sandborn WJ, Jairath V, D'Haens G, Vande Casteele N. Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. BioDrugs 2021;35:715-33. [PMID: 34797516 DOI: 10.1007/s40259-021-00507-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
36 Goodman WA, Basavarajappa SC, Liu AR, Rodriguez FDS, Mathes T, Ramakrishnan P. Sam68 contributes to intestinal inflammation in experimental and human colitis. Cell Mol Life Sci 2021. [PMID: 34693458 DOI: 10.1007/s00018-021-03976-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Kanazawa M, Tominaga K, Yamamiya A, Tanaka T, Watanabe S, Sugaya T, Abe K, Kanamori A, Arisaka T, Hoshi K, Iijima M, Goda K, Haruyama Y, Irisawa A. Analysis of Endoscopic Evaluation Reliability for Ulcerative Colitis in Histological Remission. Healthcare (Basel) 2021;9:1405. [PMID: 34828451 DOI: 10.3390/healthcare9111405] [Reference Citation Analysis]
38 Chia AYT, Ang GWX, Chan ASY, Chan W, Chong TKY, Leung YY. Managing Psoriatic Arthritis With Inflammatory Bowel Disease and/or Uveitis. Front Med (Lausanne) 2021;8:737256. [PMID: 34604268 DOI: 10.3389/fmed.2021.737256] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
39 Alhalabi M, Eddin KA, Cheha K, Abbas A. Subcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis: A case report. Medicine (Baltimore) 2021;100:e27283. [PMID: 34559136 DOI: 10.1097/MD.0000000000027283] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Chiappetta MF, Viola A, Mastronardi M, Turchini L, Carparelli S, Orlando A, Biscaglia G, Miranda A, Guida L, Costantino G, Scaldaferri F, Bossa F, Renna S, Cappello M, Alibrandi A, Orlando A, Armuzzi A, Fries W. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. Expert Opin Biol Ther 2021;:1-7. [PMID: 34521307 DOI: 10.1080/14712598.2021.1981855] [Reference Citation Analysis]
41 Cichoż-Lach H, Michalak A, Kopertowska-Majchrzak M, Eder P, Stawczyk-Eder K, Waszak K, Talar-Wojnarowska R, Zatorski H, Solarska-Półchłopek A, Chmielnicki J, Filip R, Pękala A, Janiak M, Skrobot K, Kasińska E, Krogulecki M, Królikowski P, Kłopocka M, Liebert A, Poniewierka E, Smoła I, Gąsiorowska A, Kaczka A, Wypych J, Wojciechowski K, Drygała S, Zagórowicz E. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study). Therap Adv Gastroenterol 2021;14:17562848211036456. [PMID: 34484422 DOI: 10.1177/17562848211036456] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Ishida N, Miyazu T, Tamura S, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. Real-World Efficacy and Safety Monitoring for Predicting Continuation of Tofacitinib Therapy in Patients with Ulcerative Colitis. Dig Dis Sci 2021. [PMID: 34460029 DOI: 10.1007/s10620-021-07233-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
43 Choi D, Stewart AP, Bhat S. Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis. Ann Pharmacother 2021;:10600280211041907. [PMID: 34423657 DOI: 10.1177/10600280211041907] [Reference Citation Analysis]
44 Eriksson C, Visuri I, Vigren L, Nilsson L, Kärnell A, Hjortswang H, Bergemalm D, Almer S, Hertervig E, Karlén P, Strid H, Halfvarson J; GO SWIBREG study group. Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scand J Gastroenterol 2021;56:1304-11. [PMID: 34415803 DOI: 10.1080/00365521.2021.1963466] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Rong JM, Luo J, Huang Q, Miao YL. Individualized selection of biological agents in treatment of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2021; 29(15): 893-900 [DOI: 10.11569/wcjd.v29.i15.893] [Reference Citation Analysis]
46 Vellopoulou K, Stefanou G, Tzanetakos C, Boubouchairopoulou N, Nakou M, Gourzoulidis G, Kourlaba G. Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece. Eur J Gastroenterol Hepatol 2021;33:325-33. [PMID: 32976189 DOI: 10.1097/MEG.0000000000001916] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Yao S, Zhao Z, Wang W, Liu X. Bifidobacterium Longum: Protection against Inflammatory Bowel Disease. J Immunol Res 2021;2021:8030297. [PMID: 34337079 DOI: 10.1155/2021/8030297] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
48 Ye BD, Cheon JH, Song KH, Kim JS, Kim YH, Yoon H, Lee KM, Kang SB, Jang BI, Park JJ, Kim TO, Lee DW, Foo CY, Shin JE, Park DI. The real-world outcomes of vedolizumab in patients with ulcerative colitis in Korea: a multicenter retrospective study. Therap Adv Gastroenterol 2021;14:17562848211024769. [PMID: 34285716 DOI: 10.1177/17562848211024769] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L. Drug development for ulcerative proctitis: current concepts. Gut 2021;70:1203-9. [PMID: 33789968 DOI: 10.1136/gutjnl-2021-324108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Viazis N, Pontas C, Manolakis A, Karampekos G, Tsoukali E, Galanopoulos M, Koustenis K, Archavlis E, Christidou A, Gazouli M, Mantzaris GJ. Efficacy of switching from infliximab to golimumab in patients with ulcerative colitis in deep remission. Acta Gastroenterol Belg 2021;84:423-8. [PMID: 34599566 DOI: 10.51821/84.3.007] [Reference Citation Analysis]
51 D'Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut 2021;70:1396-405. [PMID: 33431575 DOI: 10.1136/gutjnl-2019-320022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 21.0] [Reference Citation Analysis]
52 Sicilia B, Arias L, Hontoria G, García N, Badia E, Gomollón F. Are Steroids Still Useful in Immunosuppressed Patients With Inflammatory Bowel Disease? A Retrospective, Population-Based Study. Front Med (Lausanne) 2021;8:651685. [PMID: 34249960 DOI: 10.3389/fmed.2021.651685] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Stange EF. Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations. Z Gastroenterol 2021. [PMID: 34161990 DOI: 10.1055/a-1482-9273] [Reference Citation Analysis]
54 Blesl A, Binder L, Högenauer C, Wenzl H, Borenich A, Pregartner G, Berghold A, Mestel S, Kump P, Baumann-Durchschein F, Petritsch W. Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study. Aliment Pharmacol Ther 2021;54:667-77. [PMID: 34151449 DOI: 10.1111/apt.16478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
55 Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, Schoenbeck U, Ye Z, Hassan-Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy C, Chandra DE, Hung KE. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00614-5. [PMID: 34126262 DOI: 10.1016/j.cgh.2021.06.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
56 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Beaugerie L, Ricart E, Dewit O, Lopez-sanroman A, Fumery M, Carbonnel F, Buisson A, Coffin B, Roblin X, van Assche G, Esteve M, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Peyrin-biroulet L, Mary J. Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. Clinical Gastroenterology and Hepatology 2021;19:1180-1188.e4. [DOI: 10.1016/j.cgh.2020.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
57 Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol 2021;6:589-95. [PMID: 34019798 DOI: 10.1016/S2468-1253(21)00065-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
58 Modi NB, Cheng X, Mattheakis L, Hwang CC, Nawabi R, Liu D, Gupta S. Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers. Clin Pharmacol Drug Dev 2021. [PMID: 33942566 DOI: 10.1002/cpdd.946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Danne C, Rolhion N, Sokol H. Recipient factors in faecal microbiota transplantation: one stool does not fit all. Nat Rev Gastroenterol Hepatol 2021;18:503-13. [PMID: 33907321 DOI: 10.1038/s41575-021-00441-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 31.0] [Reference Citation Analysis]
60 Panés J, Vermeire S, Dubinsky MC, Loftus EV, Lawendy N, Wang W, Salese L, Su C, Modesto I, Guo X, Colombel JF. Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: Results From the OCTAVE Clinical Trials. J Crohns Colitis 2021:jjab065. [PMID: 33884415 DOI: 10.1093/ecco-jcc/jjab065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
61 George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, Sandborn WJ, Jairath V. Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease. Inflamm Bowel Dis 2020;26:515-23. [PMID: 31504528 DOI: 10.1093/ibd/izz193] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
62 Fiorino G, Danese S, Giacobazzi G, Spinelli A. Medical therapy versus surgery in moderate-to-severe ulcerative colitis. Digestive and Liver Disease 2021;53:403-8. [DOI: 10.1016/j.dld.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
63 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 Sands BE, Long MD, Reinisch W, Panés J, Loftus EV, Nduaka CI, Soonasra A, Mundayat R, Lawendy N, Chan G, Friedman GS, Su C. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program. Inflamm Bowel Dis 2021:izab056. [PMID: 33742652 DOI: 10.1093/ibd/izab056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
66 Yarlas A, Willian MK, Nag A. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. Qual Life Res 2021;30:1925-38. [PMID: 33651279 DOI: 10.1007/s11136-021-02787-4] [Reference Citation Analysis]
67 Pugliese D, Privitera G, Rogai F, Variola A, Viola A, Laterza L, Privitera AC, Allocca M, Bossa F, Cappello M, Daperno M, Lorenzon G, Mazzuoli S, Principi M, Sablich R, Moser L, Ferronato A, Traini S, Tapete G, Bodini G, Di Girolamo M, Grossi L, Mocci G, Ricci C, Saibeni S, Festa S, Spagnuolo R, Cortelezzi CC, Mocciaro F, Rizzello F, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study. United European Gastroenterol J 2021;9:102-9. [PMID: 33203342 DOI: 10.1177/2050640620974308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
68 Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, Roblin X. Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-Response. J Crohns Colitis 2020;14:542-56. [PMID: 31549158 DOI: 10.1093/ecco-jcc/jjz162] [Cited by in Crossref: 16] [Cited by in F6Publishing: 23] [Article Influence: 16.0] [Reference Citation Analysis]
69 Bröms G, Söderling J, Sachs MC, Halfvarson J, Myrelid P, Ludvigsson JF, Everhov ÅH, Olén O; SWIBREG study group. Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register - a validation study. Scand J Gastroenterol 2021;56:410-21. [PMID: 33632044 DOI: 10.1080/00365521.2021.1884894] [Reference Citation Analysis]
70 Chimenti MS, Conigliaro P, Biancone L, Perricone R. Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib. Ther Adv Musculoskelet Dis 2021;13:1759720X20977777. [PMID: 33680096 DOI: 10.1177/1759720X20977777] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
71 Taxonera C, Olivares D, Alba C. Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis. Inflamm Bowel Dis 2021:izab011. [PMID: 33586766 DOI: 10.1093/ibd/izab011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
72 Hong SJ, Krugliak Cleveland N, Akiyama S, Zullow S, Yi Y, Shaffer SR, Malter LB, Axelrad JE, Chang S, Hudesman DP, Rubin DT. Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States. Crohn's & Colitis 360 2021;3:otab002. [DOI: 10.1093/crocol/otab002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
73 Pichler J, Memaran N, Huber WD, Aufricht C, Bidmon-Fliegenschnee B. Golimumab in adolescents with Crohn's disease refractory to previous tumour necrosis factor antibody. Acta Paediatr 2021;110:661-7. [PMID: 32781480 DOI: 10.1111/apa.15522] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Shimizu H, Arai K, Takeuchi I, Minowa K, Hosoi K, Sato M, Oka I, Kaburaki Y, Shimizu T. Long-Term Durability of Infliximab for Pediatric Ulcerative Colitis: A Retrospective Data Review in a Tertiary Children's Hospital in Japan. Pediatr Gastroenterol Hepatol Nutr 2021;24:7-18. [PMID: 33505889 DOI: 10.5223/pghn.2021.24.1.7] [Reference Citation Analysis]
75 Li XZ, Qiu Y, Jeffery L, Liu F, Feng R, He JS, Tan JY, Ye ZY, Lin SN, Ghosh S, Iacucci M, Chen MH, Mao R. Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19. Front Med (Lausanne) 2020;7:613475. [PMID: 33511147 DOI: 10.3389/fmed.2020.613475] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
76 Shivaji UN, Bazarova A, Critchlow T, Smith SCL, Nardone OM, Love M, Davis J, Ghosh S, Iacucci M. Clinical outcomes, predictors of prognosis and health economics consequences in IBD patients after discontinuation of the first biological therapy. Therap Adv Gastroenterol 2020;13:1756284820981216. [PMID: 34104206 DOI: 10.1177/1756284820981216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Rundquist S, Sachs MC, Eriksson C, Olén O, Montgomery S, Halfvarson J; SWIBREG Study Group. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.Aliment Pharmacol Ther. 2021;53:471-483. [PMID: 33340426 DOI: 10.1111/apt.16193] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
78 Curtis JR, Regueiro M, Yun H, Su C, DiBonaventura M, Lawendy N, Nduaka CI, Koram N, Cappelleri JC, Chan G, Modesto I, Lichtenstein GR. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data. Inflamm Bowel Dis 2021;27:1394-408. [PMID: 33324993 DOI: 10.1093/ibd/izaa289] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
79 Jacob EM, Borah A, Pillai SC, Kumar DS. Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy. Nanomaterials (Basel) 2020;10:E2460. [PMID: 33316984 DOI: 10.3390/nano10122460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
80 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
81 Kucharzik T, Dignaß A, Siegmund B. Aktualisierung der Colitis ulcerosa Leitlinie 2020. Z Gastroenterol 2020;58:1209-32. [DOI: 10.1055/a-1296-3494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
82 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
83 Sakemi R, Miyakawa M, Tanaka H, Nasuno M, Motoya S, Tanuma T, Ishii M, Yanagisawa H, Yamashita M, Toita N, Suzuki R, Kobayashi T, Nojima M, So S. Predicting a rapid response to adalimumab treatment and favorable short-term outcomes through the high platelet count in patients with ulcerative colitis: A multicenter retrospective cohort study. Medicine (Baltimore) 2020;99:e23344. [PMID: 33217875 DOI: 10.1097/MD.0000000000023344] [Reference Citation Analysis]
84 Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.Dtsch Arztebl Int. 2020;117:564-574. [PMID: 33148393 DOI: 10.3238/arztebl.2020.0564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
85 Hernandez L, Kuwabara H, Shah A, Yamabe K, Burnett H, Fahrbach K, Koufopoulou M, Iwakiri R. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. Pharmacoeconomics 2020;38:69-84. [PMID: 31552601 DOI: 10.1007/s40273-019-00841-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
86 Castro-Dopico T, Colombel JF, Mehandru S. Targeting B cells for inflammatory bowel disease treatment: back to the future. Curr Opin Pharmacol 2020;55:90-8. [PMID: 33166872 DOI: 10.1016/j.coph.2020.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
87 Bhattacharya A, Osterman MT. Biologic Therapy for Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:717-29. [PMID: 33121691 DOI: 10.1016/j.gtc.2020.08.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
88 Singh S, Bhatia R, Khare P, Sharma S, Rajarammohan S, Bishnoi M, Bhadada SK, Sharma SS, Kaur J, Kondepudi KK. Anti-inflammatory Bifidobacterium strains prevent dextran sodium sulfate induced colitis and associated gut microbial dysbiosis in mice. Sci Rep 2020;10:18597. [PMID: 33122795 DOI: 10.1038/s41598-020-75702-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
89 Iborra M, García-Morales N, Rubio S, Bertoletti F, Calvo M, Taxonera C, Boscá-Watts MM, Sierra M, Mancenido N, Beltrán B, Nantes Castillejo Ó, García-Planella E, Vera I, Alba C, Martí-Aguado D, Ballester MP, Cano-Sanz N, Pajares-Villarroya R, Cerrillo E, Cañada A, Nos P. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients. Sci Rep 2020;10:17774. [PMID: 33082359 DOI: 10.1038/s41598-020-73577-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
90 Moriichi K, Fujiya M, Okumura T. The endoscopic diagnosis of mucosal healing and deep remission in inflammatory bowel disease. Dig Endosc 2021;33:1008-23. [PMID: 33020947 DOI: 10.1111/den.13863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
91 Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W; CONDUCT study group. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol 2020;5:1063-75. [PMID: 33031757 DOI: 10.1016/S2468-1253(20)30301-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
92 . Ueg Week 2020 Poster Presentations. United European Gastroenterol j 2020;8:144-887. [DOI: 10.1177/2050640620927345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, D'Haens G, Feagan BG, Sandborn WJ, Jairath V, Singh S. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. Am J Gastroenterol 2020;115:885-94. [PMID: 32384283 DOI: 10.14309/ajg.0000000000000596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
94 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
95 Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D'Haens GR, Tuttle JL, Krueger K, Friedrich S, Durante M, Arora V, Naegeli AN, Schmitz J, Feagan BG. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31289-1. [PMID: 32950748 DOI: 10.1016/j.cgh.2020.09.028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
96 Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis.Nat Rev Dis Primers. 2020;6:74. [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 206] [Article Influence: 26.0] [Reference Citation Analysis]
97 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
98 Yamairi F, Yano T, Goto T, Iwasaki T. Dose Adjustment of Methotrexate Administered Concomitantly with Golimumab for Rheumatoid Arthritis in Japanese Real-World Clinical Settings. Rheumatol Ther 2020;7:811-24. [PMID: 32844379 DOI: 10.1007/s40744-020-00228-1] [Reference Citation Analysis]
99 Petryszyn P, Ekk-Cierniakowski P, Zurakowski G. Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland. Therap Adv Gastroenterol 2020;13:1756284820941179. [PMID: 32922513 DOI: 10.1177/1756284820941179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
100 Li K, Marano C, Zhang H, Yang F, Sandborn WJ, Sands BE, Feagan BG, Rubin DT, Peyrin-Biroulet L, Friedman JR, De Hertogh G. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology 2020;159:2052-64. [PMID: 32853634 DOI: 10.1053/j.gastro.2020.08.037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
101 Labarile N, Ghosh S, Ng SC, Walters J, Iacucci M. Tests that now deserve to be more widely adopted in IBD clinical practice. Therap Adv Gastroenterol 2020;13:1756284820944088. [PMID: 32782481 DOI: 10.1177/1756284820944088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Hyams JS, O’brien CD, Padgett L, Rosh JR, Turner D, Veereman G, Griffiths AM, Heyman MB, Wahbeh G, Adedokun OJ, Strauss RS, Lynch JP, Chan D. Maintenance Golimumab Treatment in Pediatric UC Patients With Moderately to Severely Active UC: PURSUIT PEDS PK Long-Term Study Results. Crohn's & Colitis 360 2020;2:otaa063. [DOI: 10.1093/crocol/otaa063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Ianiro G, Segal JP, Mullish BH, Quraishi MN, Porcari S, Fabiani G, Gasbarrini A, Cammarota G. Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders. Future Microbiol 2020;15:1173-83. [PMID: 32954843 DOI: 10.2217/fmb-2020-0061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
104 Roberti R, Iannone LF, Palleria C, De Sarro C, Spagnuolo R, Barbieri MA, Vero A, Manti A, Pisana V, Fries W, Trifirò G, Naturale MD, Larussa T, De Francesco AE, Bosco V, Donato di Paola E, Citraro R, Luzza F, Bennardo L, Rodinò S, Doldo P, Spina E, Russo E, De Sarro G. Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Curr Med Res Opin 2020;36:1457-63. [PMID: 32573307 DOI: 10.1080/03007995.2020.1786681] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
105 Biancone L, Ardizzone S, Armuzzi A, Castiglione F, D'Incà R, Danese S, Daperno M, Gionchetti P, Rizzello F, Scribano ML, Vecchi M, Orlando A. Ustekinumab for treating ulcerative colitis: an expert opinion. Expert Opin Biol Ther 2020;20:1321-9. [PMID: 32662683 DOI: 10.1080/14712598.2020.1792882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 D'Amico F, Danese S, Peyrin-Biroulet L. Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials. J Clin Med 2020;9:E2350. [PMID: 32717997 DOI: 10.3390/jcm9082350] [Reference Citation Analysis]
107 Nakase H, Matsumoto T, Watanabe K, Hisamatsu T. The shining DIAMOND for evidence-based treatment strategies for Crohn's disease. J Gastroenterol 2020;55:824-32. [PMID: 32661927 DOI: 10.1007/s00535-020-01702-x] [Reference Citation Analysis]
108 Gracey E, Vereecke L, McGovern D, Fröhling M, Schett G, Danese S, De Vos M, Van den Bosch F, Elewaut D. Revisiting the gut-joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol 2020;16:415-33. [PMID: 32661321 DOI: 10.1038/s41584-020-0454-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 47] [Article Influence: 12.0] [Reference Citation Analysis]
109 Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, Kroeker K, Halloran B, Panaccione R, Peyrin-Biroulet L, Ma C, Ananthakrishnan AN. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. Clin Gastroenterol Hepatol 2021;19:1366-1376.e2. [PMID: 32668338 DOI: 10.1016/j.cgh.2020.07.012] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
110 Dolovich C, Bernstein CN, Singh H, Nugent Z, Tennakoon A, Shafer LA, Marrie RA, Sareen J, Targownik LE. Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2021;19:1200-1208.e1. [PMID: 32668341 DOI: 10.1016/j.cgh.2020.07.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
111 Di Jiang C, Raine T. IBD considerations in spondyloarthritis. Ther Adv Musculoskelet Dis 2020;12:1759720X20939410. [PMID: 32695235 DOI: 10.1177/1759720X20939410] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
112 Samaan MA, Cunningham G, Tamilarasan AG, Beltran L, Pavlidis P, Ray S, Mawdsley J, Anderson SH, Sanderson JD, Arkir Z, Irving PM. Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study. Aliment Pharmacol Ther 2020;52:292-302. [PMID: 32506695 DOI: 10.1111/apt.15808] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
113 Vachon A, Scott FI. The treatment approach to inflammatory bowel disease in 2020. Curr Opin Gastroenterol 2020;36:247-56. [PMID: 32452863 DOI: 10.1097/MOG.0000000000000653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
114 Han M, Jung YS, Cheon JH, Park S. Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study. Yonsei Med J 2020;61:382-90. [PMID: 32390361 DOI: 10.3349/ymj.2020.61.5.382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
115 Danese S, Fiorino G, Peyrin-biroulet L. Positioning Therapies in Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:1280-1290.e1. [DOI: 10.1016/j.cgh.2020.01.017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
116 Cheng D, Cushing KC, Cai T, Ananthakrishnan AN. Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials. Clin Gastroenterol Hepatol 2021;19:939-946.e4. [PMID: 32371165 DOI: 10.1016/j.cgh.2020.04.070] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
117 Yarlas A, Maher S, Bayliss M, Lovley A, Cappelleri JC, Bushmakin AG, DiBonaventura MD. The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis. J Patient Cent Res Rev 2020;7:189-205. [PMID: 32377552 DOI: 10.17294/2330-0698.1722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
118 Porter RJ, Kalla R, Ho GT. Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Res 2020;9:F1000 Faculty Rev-294. [PMID: 32399194 DOI: 10.12688/f1000research.20805.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
119 Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis 2018;12:1021-9. [PMID: 29767728 DOI: 10.1093/ecco-jcc/jjy049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
120 . UEG Week 2019 Oral Presentations. United European Gastroenterol J 2019;7:10-188. [PMID: 32213000 DOI: 10.1177/2050640619854670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
121 Kanmura S, Tanaka A, Yutsudou K, Kuwazuru K, Komaki F, Komaki Y, Iwaya H, Arima S, Sasaki F, Tanoue S, Hashimoto S, Ido A. Significance of Linked Color Imaging for Predicting the Risk of Clinical Relapse in Ulcerative Colitis. Gastroenterol Res Pract 2020;2020:3108690. [PMID: 32211040 DOI: 10.1155/2020/3108690] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Hupé M, Rivière P, Nancey S, Roblin X, Altwegg R, Filippi J, Fumery M, Bouguen G, Peyrin-Biroulet L, Bourreille A, Caillo L, Simon M, Goutorbe F, Laharie D. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Aliment Pharmacol Ther 2020;51:852-60. [PMID: 32201971 DOI: 10.1111/apt.15680] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
123 Macaluso FS, Maida M, Ventimiglia M, Renna S, Cottone M, Orlando A. Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. Inflamm Bowel Dis 2019;25:987-97. [PMID: 30590590 DOI: 10.1093/ibd/izy365] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
124 Shivaji UN, Nardone OM, Cannatelli R, Smith SC, Ghosh S, Iacucci M. Small molecule oral targeted therapies in ulcerative colitis. Lancet Gastroenterol Hepatol 2020;5:850-61. [PMID: 32171056 DOI: 10.1016/S2468-1253(19)30414-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
125 Pugliese N, Roda G, Peyrin-biroulet L, Danese S. Emerging therapies for the treatment of ulcerative colitis. Expert Opinion on Emerging Drugs 2020;25:71-9. [DOI: 10.1080/14728214.2020.1737009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
126 Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, Collins M, Fumery M, Poullenot F, Armengol L, Buisson A, Abitbol V, Laharie D, Seksik P, Nancey S, Blanc P, Bouhnik Y, Pariente B, Peyrin-biroulet L, Nachury M, Boschetti G, Flourié B, Danion P, Savoye G, brazier F, Loreau J, Beaugerie L, Sokol H, Nion-larmurier I, Bourrier A, Landman C, Lefèvre J, Chafai N, Bouta N, Funakoshi N. Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. Clinical Gastroenterology and Hepatology 2020;18:620-627.e1. [DOI: 10.1016/j.cgh.2019.05.060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
127 Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, Danese S. Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opin Biol Ther 2020;20:413-20. [PMID: 32093531 DOI: 10.1080/14712598.2020.1732919] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
128 Philip G, Cornillie F, Adedokun JO, Melsheimer R, Rutgeerts P, Colombel JF, Marano C. Early Dose Optimisation of Golimumab in Nonresponders to Induction Treatment for Ulcerative Colitis Is Effective and Supported by Pharmacokinetic Data. J Crohns Colitis 2019;13:1257-64. [PMID: 30847474 DOI: 10.1093/ecco-jcc/jjz052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
129 Kaiko GE, Chen F, Lai CW, Chiang IL, Perrigoue J, Stojmirović A, Li K, Muegge BD, Jain U, VanDussen KL, Goggins BJ, Keely S, Weaver J, Foster PS, Lawrence DA, Liu TC, Stappenbeck TS. PAI-1 augments mucosal damage in colitis. Sci Transl Med 2019;11:eaat0852. [PMID: 30842312 DOI: 10.1126/scitranslmed.aat0852] [Cited by in Crossref: 19] [Cited by in F6Publishing: 29] [Article Influence: 9.5] [Reference Citation Analysis]
130 Lefevre PLC, Shackelton LM, Vande Casteele N. Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine. BioDrugs 2019;33:453-68. [PMID: 31301024 DOI: 10.1007/s40259-019-00366-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
131 Fukuda T, Naganuma M, Sugimoto S, Ono K, Nanki K, Mizuno S, Kimura K, Mutaguchi M, Nakazato Y, Takabayashi K, Inoue N, Ogata H, Iwao Y, Kanai T. Efficacy of Therapeutic Intervention for Patients With an Ulcerative Colitis Mayo Endoscopic Score of 1. Inflamm Bowel Dis. 2019;25:782-788. [PMID: 30265308 DOI: 10.1093/ibd/izy300] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
132 Sands BE, Cheifetz AS, Nduaka CI, Quirk D, Wang W, Maller E, Friedman GS, Su C, Higgins PDR. The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. J Crohns Colitis 2019;13:1217-26. [PMID: 30879034 DOI: 10.1093/ecco-jcc/jjz038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
133 Frasca JD, Cheifetz AS. The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth. Ann Transl Med 2019;7:S388. [PMID: 32016106 DOI: 10.21037/atm.2019.12.86] [Reference Citation Analysis]
134 Zhou HY, Guo B, Lufumpa E, Li XM, Chen LH, Meng X, Li BZ. Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis. Immunol Invest 2021;50:323-37. [PMID: 32009472 DOI: 10.1080/08820139.2020.1714650] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
135 Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M, Morgan-cox M, Laskowski J, Schmitz J, D’haens GR. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology 2020;158:537-549.e10. [DOI: 10.1053/j.gastro.2019.08.043] [Cited by in Crossref: 38] [Cited by in F6Publishing: 63] [Article Influence: 19.0] [Reference Citation Analysis]
136 Murthy SK, Begum J, Benchimol EI, Bernstein CN, Kaplan GG, McCurdy JD, Singh H, Targownik L, Taljaard M. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut 2020;69:274-82. [PMID: 31196874 DOI: 10.1136/gutjnl-2019-318440] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 40.0] [Reference Citation Analysis]
137 Chang S, Hudesman D. First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Curr Gastroenterol Rep 2020;22:7. [PMID: 32002688 DOI: 10.1007/s11894-020-0745-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
138 Welty M, Mesana L, Padhiar A, Naessens D, Diels J, van Sanden S, Pacou M. Efficacy of ustekinumab vs. advanced therapies for the treatment of moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Curr Med Res Opin 2020;36:595-606. [PMID: 31960724 DOI: 10.1080/03007995.2020.1716701] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
139 Adedokun OJ, Xu Z, Liao S, Strauss R, Reinisch W, Feagan BG, Sandborn WJ. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis. Clin Ther 2020;42:157-174.e4. [PMID: 31982148 DOI: 10.1016/j.clinthera.2019.11.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
140 Angus HCK, Butt AG, Schultz M, Kemp RA. Intestinal Organoids as a Tool for Inflammatory Bowel Disease Research. Front Med (Lausanne) 2019;6:334. [PMID: 32010704 DOI: 10.3389/fmed.2019.00334] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
141 Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol 2020;18:2179-2191.e6. [PMID: 31945470 DOI: 10.1016/j.cgh.2020.01.008] [Cited by in Crossref: 100] [Cited by in F6Publishing: 81] [Article Influence: 50.0] [Reference Citation Analysis]
142 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 11.5] [Reference Citation Analysis]
143 Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94:1357-1373. [PMID: 31272578 DOI: 10.1016/j.mayocp.2019.01.018] [Cited by in Crossref: 54] [Cited by in F6Publishing: 101] [Article Influence: 27.0] [Reference Citation Analysis]
144 Long MD, Rubin DT. Histologic Remission in Ulcerative Colitis: Are We There Yet? Am J Gastroenterol 2019;114:713-5. [PMID: 31021831 DOI: 10.14309/ajg.0000000000000235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
145 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
146 Shibuya T, Nomura K, Okahara K, Haga K, Nomura O, Murakami T, Uchida S, Kodani T, Ishikawa D, Sakamoto N, Ogihara T, Osada T, Nagahara A. Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy. Med Sci Monit 2019;25:9855-63. [PMID: 31865359 DOI: 10.12659/MSM.918562] [Reference Citation Analysis]
147 Jain A, Marrie RA, Shafer LA, Graff LA, Patten SB, El-Gabalawy R, Sareen J, Bolton JM, Fisk JD, Bernstein CN. Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review. Crohns Colitis 360 2020;2:otz053. [PMID: 32003760 DOI: 10.1093/crocol/otz053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
148 Allen PB, Bonovas S, Danese S, Peyrin-Biroulet L. Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective. Expert Opin Biol Ther 2020;20:151-61. [PMID: 31815548 DOI: 10.1080/14712598.2020.1702020] [Reference Citation Analysis]
149 Naganuma M, Yokoyama Y, Motoya S, Watanabe K, Sawada K, Hirai F, Yamamoto T, Hanai H, Omori T, Kanai T, Hibi T; CAPTAIN study Group. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. J Gastroenterol. 2020;55:390-400. [PMID: 31811562 DOI: 10.1007/s00535-019-01651-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
150 Ivashkin VT, Shelygin YA, Belousova EA, Abdulganieva DI, Alekseeva OA, Achkasov SI, Valuiskikh EY, Vardanyan AV, Veselov AV, Veselov VV, Golovenko OV, Gubonina IV, Zhigalova TN, Kashnikov VN, Knyazev OV, Makarchuk PA, Moskaliev AI, Nanaeva BA, Nizov AA, Nikitina NV, Nikolaeva NN, Pavlenko VV, Poluektova EA, Svetlova IO, Tarasova LV, Tkachev AV, Frolov SA, Khlynova OV, Chashkova EY, Shapina MV, Sheptulin AA, Shifrin OS, Shchukina OB. PROJECT: CLINICAL GUIDELINES FOR THE DIAGNOSTICS AND TREATMENT OF ULCERATIVE COLITIS. Koloproktologiâ 2019;18:7-36. [DOI: 10.33878/2073-7556-2019-18-4-7-36] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 5.3] [Reference Citation Analysis]
151 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 555] [Article Influence: 205.7] [Reference Citation Analysis]
152 Neurath MF. Resolution of inflammation: from basic concepts to clinical application. Semin Immunopathol 2019;41:627-31. [DOI: 10.1007/s00281-019-00771-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
153 Digby-Bell JL, Atreya R, Monteleone G, Powell N. Interrogating host immunity to predict treatment response in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:9-20. [PMID: 31767987 DOI: 10.1038/s41575-019-0228-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 16.3] [Reference Citation Analysis]
154 Dulai PS, Singh S, Jairath V, Ma C, Narula N, Vande Casteele N, Peyrin-Biroulet L, Vermeire S, D'Haens G, Feagan BG, Sandborn WJ. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Aliment Pharmacol Ther 2020;51:435-45. [PMID: 31755121 DOI: 10.1111/apt.15577] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
155 Yuan Z, Yang L, Zhang X, Ji P, Hua Y, Wei Y. Huang-Lian-Jie-Du Decoction Ameliorates Acute Ulcerative Colitis in Mice via Regulating NF-κB and Nrf2 Signaling Pathways and Enhancing Intestinal Barrier Function. Front Pharmacol 2019;10:1354. [PMID: 31849642 DOI: 10.3389/fphar.2019.01354] [Cited by in Crossref: 16] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
156 Actis GC, Pellicano R, Fagoonee S, Ribaldone DG. History of Inflammatory Bowel Diseases. J Clin Med. 2019;8:1970. [PMID: 31739460 DOI: 10.3390/jcm8111970] [Cited by in Crossref: 31] [Cited by in F6Publishing: 47] [Article Influence: 10.3] [Reference Citation Analysis]
157 Bossa F, Biscaglia G, Valvano MR, Costantino G, Lauria A, Clemente R, Ferracane C, Shahini E, Mendolaro M, Grossi L, Mazzuoli S, Rispo A, Pranzo G, Sebkova L, Tursi A, Miranda A, Patturelli M, Spagnuolo R, Ricciardelli C, Sgarro C, Paese P, Inserra G, Azzarone A, Nardone O, Fries W, Buccianti N, Privitera AC, Principi MB, Cappello M, Guglielmi FW, Romano M, Riegler G, Fanigliulo L, Melina R, Andriulli A. Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. Dig Dis Sci 2020;65:1767-76. [PMID: 31722059 DOI: 10.1007/s10620-019-05904-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
158 Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther 2020;51:271-80. [PMID: 31660640 DOI: 10.1111/apt.15555] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
159 Jerger L, Hyams JS. Special considerations for biologic medications in pediatric ulcerative colitis. Expert Opin Biol Ther 2020;20:429-35. [PMID: 31652087 DOI: 10.1080/14712598.2020.1685492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
160 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 106] [Cited by in F6Publishing: 134] [Article Influence: 35.3] [Reference Citation Analysis]
161 Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
162 Picardo S, Seow CH. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. Drugs 2019;79:1053-63. [PMID: 31183768 DOI: 10.1007/s40265-019-01141-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
163 Eichele DD, Young R. Medical Management of Inflammatory Bowel Disease. Surg Clin North Am 2019;99:1223-35. [PMID: 31676060 DOI: 10.1016/j.suc.2019.08.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
164 Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opinion on Biological Therapy 2020;20:363-78. [DOI: 10.1080/14712598.2019.1666101] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
165 Naganuma M, Sugimoto S, Fukuda T, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Abe T, Suzuki Y, Kanai T; INDIGO Study Group. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. J Gastroenterol 2020;55:169-80. [PMID: 31529220 DOI: 10.1007/s00535-019-01625-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
166 Perin RL, Damião AOMC, Flores C, Ludvig JC, Magro DO, Miranda EF, Moraes ACD, Nones RB, Teixeira FV, Zeroncio M, Kotze PG. VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY. Arq Gastroenterol 2019;56:312-7. [DOI: 10.1590/s0004-2803.201900000-58] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
167 Walia D, Kaur G, Jaggi AS, Bali A. Exploring the therapeutic potential of sodium benzoate in acetic acid-induced ulcerative colitis in rats. J Basic Clin Physiol Pharmacol 2019;30. [PMID: 31469656 DOI: 10.1515/jbcpp-2019-0086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
168 Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Tavares de Sousa H, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Philip G, Lopes J, Carneiro F. Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. Therap Adv Gastroenterol 2019;12:1756284819869141. [PMID: 31516554 DOI: 10.1177/1756284819869141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
169 Tesser J, Kafka S, DeHoratius RJ, Xu S, Hsia EC, Turkiewicz A. Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age. Arthritis Res Ther 2019;21:190. [PMID: 31429794 DOI: 10.1186/s13075-019-1968-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
170 Dreesen E, Kantasiripitak W, Detrez I, Stefanović S, Vermeire S, Ferrante M, Bouillon T, Drobne D, Gils A. A Population Pharmacokinetic and Exposure–Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases 2019. [DOI: 10.1093/ibd/izz144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
171 Kanmura S, Hamamoto H, Tanaka A, Arima S, Sasaki F, Tanoue S, Nasu Y, Hashimoto S, Higashi M, Ido A. Diagnostic utility of linked color imaging in the evaluation of colonic mucosal inflammation in ulcerative colitis: a pilot study. Endosc Int Open 2019;7:E937-43. [PMID: 31367672 DOI: 10.1055/a-0810-0398] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
172 Berger A, Duru G, de Vries A, Marini JC, Aoucheta D, Cornillie F, Nancey S, Detrez I, Gils A, Roblin X, Paul S. Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational Study. Therapeutic Drug Monitoring 2019;41:459-66. [DOI: 10.1097/ftd.0000000000000629] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
173 Lohan C, Diamantopoulos A, LeReun C, Wright E, Bohm N, Sawyer LM. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol 2019;6:e000302. [PMID: 31413856 DOI: 10.1136/bmjgast-2019-000302] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
174 Schultheiss JPD, Brand EC, Lamers E, van den Berg WCM, van Schaik FDM, Oldenburg B, Fidder HH. Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects. Aliment Pharmacol Ther 2019;50:386-96. [PMID: 31310690 DOI: 10.1111/apt.15380] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
175 Cammarota G, Ianiro G. FMT for ulcerative colitis: closer to the turning point. Nat Rev Gastroenterol Hepatol 2019;16:266-8. [PMID: 30850823 DOI: 10.1038/s41575-019-0131-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
176 Grossi V, Gulli F, Infantino M, Stefanile A, Napodano C, Benucci M, Pocino K, Li Gobbi F, Damiani A, Di Pino A, Manfredi M, Marino M, Basile V, Rapaccini GL, Basile U. The Laboratory Role in anti-TNF Biological Therapy Era. Immunological Investigations 2020;49:317-32. [DOI: 10.1080/08820139.2019.1637434] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
177 Schreiner P, Neurath MF, Ng SC, El-Omar EM, Sharara AI, Kobayashi T, Hisamatsu T, Hibi T, Rogler G. Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. Inflamm Intest Dis 2019;4:79-96. [PMID: 31559260 DOI: 10.1159/000500721] [Cited by in Crossref: 23] [Cited by in F6Publishing: 35] [Article Influence: 7.7] [Reference Citation Analysis]
178 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL; Asia-Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn's and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. J Gastroenterol Hepatol 2019;34:1296-315. [PMID: 30848854 DOI: 10.1111/jgh.14648] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
179 Teixeira FV, Vilela EG, Damião AOMC, Vieira A, Albuquerque IC, Parente JML, Chebli JMF, Ambrogini Junior O, Hossne RS, Miszputen SJ. Ulcerative colitis - treatment with biologicals. Rev Assoc Med Bras (1992) 2019;65:547-53. [PMID: 31066808 DOI: 10.1590/1806-9282.65.4.547] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
180 Franca R, Curci D, Lucafò M, Decorti G, Stocco G. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opin Drug Metab Toxicol 2019;15:527-39. [PMID: 31177858 DOI: 10.1080/17425255.2019.1630378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
181 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
182 Berends SE, Strik AS, Jansen JM, de Boer NK, van Egmond PS, Brandse JF, Mathôt RA, D’haens GR, Löwenberg M. Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study. Scandinavian Journal of Gastroenterology 2019;54:700-6. [DOI: 10.1080/00365521.2019.1619828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
183 Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int J Mol Sci 2019;20:E2529. [PMID: 31126015 DOI: 10.3390/ijms20102529] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
184 Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V. Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. Clin Gastroenterol Hepatol 2020;18:424-431.e7. [PMID: 31108227 DOI: 10.1016/j.cgh.2019.05.019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
185 Milev S, DiBonaventura MD, Quon P, Wern Goh J, Bourret J, Peeples-Lamirande K, Soonasra A, Cappelleri JC, Quirk D. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States. J Med Econ. 2019;22:859-868. [PMID: 31012362 DOI: 10.1080/13696998.2019.1609481] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
186 Bots S, Gecse K, Barclay M, D'Haens G. Combination Immunosuppression in IBD. Inflamm Bowel Dis 2018;24:539-45. [PMID: 29462391 DOI: 10.1093/ibd/izx065] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
187 Trigo-Vicente C, Gimeno-Ballester V, López-Del Val A. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain. Eur J Hosp Pharm 2020;27:355-60. [PMID: 33097619 DOI: 10.1136/ejhpharm-2018-001833] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
188 Tran V, Shammas RM, Sauk JS, Padua D. Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy. Clin Exp Gastroenterol 2019;12:179-91. [PMID: 31118734 DOI: 10.2147/CEG.S150908] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
189 Shah J, Thakur ML, Dutta U. Mucosal healing in inflammatory bowel disease: Expanding horizon. Indian J Gastroenterol 2019;38:98-109. [PMID: 31037509 DOI: 10.1007/s12664-019-00950-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
190 Naganuma M. Treatment with indigo naturalis for inflammatory bowel disease and other immune diseases. Immunol Med 2019;42:16-21. [PMID: 31034341 DOI: 10.1080/25785826.2019.1599158] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
191 Kim WM, Kaser A, Blumberg RS. A role for oncostatin M in inflammatory bowel disease. Nat Med 2017;23:535-6. [PMID: 28475567 DOI: 10.1038/nm.4338] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
192 Romano B, Lleo A, Sala E, D’amico G, Marino DI, Ciccocioppo R, Vetrano S. Mesenchymal Stem Cells to Treat Digestive System Disorders: Progress Made and Future Directions. Curr Transpl Rep 2019;6:134-45. [DOI: 10.1007/s40472-019-00238-1] [Reference Citation Analysis]
193 Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Sousa HT, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Cornillie F, Lopes J, Carneiro F; Portuguese IBD Group [GEDII]. Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study. Journal of Crohn's and Colitis 2019;13:1387-93. [DOI: 10.1093/ecco-jcc/jjz071] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
194 Dwadasi S, Israel A, Rubin DT. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know? Gastrointest Endosc Clin N Am 2019;29:405-19. [PMID: 31078244 DOI: 10.1016/j.giec.2019.03.001] [Reference Citation Analysis]
195 Taxonera C, Iborra M, Bosca-Watts MM, Rubio S, Nantes Ó, Higuera R, Bertoletti F, Martínez-Montiel P, Sierra-Ausin M, Manceñido N, Lázaro Pérez-Calle J, Algaba A, Olivares D, Alba C. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis. Curr Med Res Opin 2019;35:1297-304. [PMID: 30722703 DOI: 10.1080/03007995.2019.1579557] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
196 Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 91] [Article Influence: 16.7] [Reference Citation Analysis]
197 Estevinho MM, Afonso J, Rosa I, Lago P, Trindade E, Correia L, Dias CC, Magro F; GEDII [Portuguese IBD Group]. Placebo Effect on the Health-related Quality of Life of Inflammatory Bowel Disease Patients: A Systematic Review With Meta-analysis. J Crohns Colitis 2018;12:1232-44. [PMID: 30010736 DOI: 10.1093/ecco-jcc/jjy100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
198 Ahmad H, Kumar VL. Pharmacotherapy of ulcerative colitis - current status and emerging trends. J Basic Clin Physiol Pharmacol 2018;29:581-92. [PMID: 30089097 DOI: 10.1515/jbcpp-2016-0014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
199 Adedokun OJ, Gunn GR, Leu JH, Gargano C, Xu Z, Sandborn WJ, Rutgeerts P, Shankar G. Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases 2019;25:1532-40. [DOI: 10.1093/ibd/izz003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
200 Li K, Strauss R, Marano C, Greenbaum LE, Friedman JR, Peyrin-biroulet L, Brodmerkel C, De Hertogh G. A Simplified Definition of Histologic Improvement in Ulcerative Colitis and its Association With Disease Outcomes up to 30 Weeks from Initiation of Therapy: Post Hoc Analysis of Three Clinical Trials. Journal of Crohn's and Colitis 2019;13:1025-35. [DOI: 10.1093/ecco-jcc/jjz022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
201 Cunningham G, Samaan MA, Irving PM. Golimumab in the treatment of ulcerative colitis. Therap Adv Gastroenterol 2019;12:1756284818821266. [PMID: 30728858 DOI: 10.1177/1756284818821266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
202 Fukuda T, Naganuma M, Kanai T. Current new challenges in the management of ulcerative colitis. Intest Res 2019;17:36-44. [PMID: 30678445 DOI: 10.5217/ir.2018.00126] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
203 Murthy SK, Shukla T, Antonova L, Belair MA, Ramsay T, Gallinger Z, Nguyen GC, Benchimol EI. Predictive models of disease burden at diagnosis in persons with adult-onset ulcerative colitis using health administrative data. BMC Gastroenterol 2019;19:13. [PMID: 30665357 DOI: 10.1186/s12876-018-0924-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
204 Ma C, Guizzetti L, Cipriano LE, Parker CE, Nguyen TM, Gregor JC, Chande N, Feagan BG, Jairath V. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Aliment Pharmacol Ther 2019;49:364-74. [PMID: 30569460 DOI: 10.1111/apt.15090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
205 Detrez I, Schops G, Lefrère J, Tops S, Van Assche G, Vermeire S, Van Moerkercke W, Ferrante M, Gils A. Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information. AAPS J 2018;21:10. [PMID: 30564993 DOI: 10.1208/s12248-018-0282-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
206 Jansen JP, Khalid JM, Smyth MD, Patel H. The number needed to treat and relevant between-trial comparisons of competing interventions. Clinicoecon Outcomes Res 2018;10:865-71. [PMID: 30588048 DOI: 10.2147/CEOR.S180491] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
207 Buurman DJ, Blokzijl T, Festen EAM, Pham BT, Faber KN, Brouwer E, Dijkstra G. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar. PLoS One 2018;13:e0208922. [PMID: 30533022 DOI: 10.1371/journal.pone.0208922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
208 Xu Y, Adedokun OJ, Chan D, Hu C, Xu Z, Strauss RS, Hyams JS, Turner D, Zhou H. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis. J Clin Pharmacol 2019;59:590-604. [PMID: 30536638 DOI: 10.1002/jcph.1353] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
209 Scharnhorst V, Schmitz EMH, van de Kerkhof D, Derijks LJJ, Broeren MAC. A value proposition for trough level-based anti-TNFα drug dosing. Clin Chim Acta 2019;489:89-95. [PMID: 30521801 DOI: 10.1016/j.cca.2018.11.038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
210 Lucafò M, Franca R, Selvestrel D, Curci D, Pugnetti L, Decorti G, Stocco G. Pharmacogenetics of treatments for inflammatory bowel disease. Expert Opin Drug Metab Toxicol 2018;14:1209-23. [PMID: 30465611 DOI: 10.1080/17425255.2018.1551876] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
211 Selinger CP, Carbery I, Al-Asiry J. The role of biologics in the treatment of patients with inflammatory bowel disease. Br J Hosp Med (Lond) 2018;79:686-93. [PMID: 30526103 DOI: 10.12968/hmed.2018.79.12.686] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
212 Trigo-vicente C, Gimeno-ballester V, García-lópez S, López-del Val A. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis. Int J Clin Pharm 2018;40:1411-9. [DOI: 10.1007/s11096-018-0743-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
213 Sandborn WJ, Panés J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol 2019;17:1541-50. [PMID: 30476584 DOI: 10.1016/j.cgh.2018.11.035] [Cited by in Crossref: 121] [Cited by in F6Publishing: 105] [Article Influence: 30.3] [Reference Citation Analysis]
214 Olivera P, Danese S, Pouillon L, Bonovas S, Peyrin-Biroulet L. Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence. Dig Liver Dis. 2019;51:327-334. [PMID: 30555013 DOI: 10.1016/j.dld.2018.11.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
215 Pike KA, Tremblay ML. Protein Tyrosine Phosphatases: Regulators of CD4 T Cells in Inflammatory Bowel Disease. Front Immunol. 2018;9:2504. [PMID: 30429852 DOI: 10.3389/fimmu.2018.02504] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
216 Hu C, Adedokun OJ, Zhang L, Sharma A, Zhou H. Modeling near-continuous clinical endpoint as categorical: application to longitudinal exposure-response modeling of Mayo scores for golimumab in patients with ulcerative colitis. J Pharmacokinet Pharmacodyn 2018;45:803-16. [PMID: 30377888 DOI: 10.1007/s10928-018-9610-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
217 Paschos P, Katsoula A, Salanti G, Giouleme O, Athanasiadou E, Tsapas A. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment Pharmacol Ther. 2018;48:1174-1185. [PMID: 30378141 DOI: 10.1111/apt.15005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
218 Viola A, Pugliese D, Renna S, Furfaro F, Caprioli F, D'Incà R, Bossa F, Mazza S, Costantino G, Fantini MC, Fiorino G, Alibrandi A, Orlando A, Armuzzi A, Fries W. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Dig Liver Dis 2019;51:510-5. [PMID: 30472389 DOI: 10.1016/j.dld.2018.10.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
219 Rundquist S, Eriksson C, Nilsson L, Angelison L, Jäghult S, Björk J, Grip O, Hjortswang H, Strid H, Karlén P, Montgomery S, Halfvarson J. Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scandinavian Journal of Gastroenterology 2018;53:1257-63. [DOI: 10.1080/00365521.2018.1519597] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
220 Jairath V, Jeyarajah J, Zou G, Parker CE, Olson A, Khanna R, D'Haens GR, Sandborn WJ, Feagan BG. A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. Lancet Gastroenterol Hepatol 2019;4:63-70. [PMID: 30343116 DOI: 10.1016/S2468-1253(18)30306-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
221 Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM; Swiss IBD Cohort Study Group. Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. Eur J Gastroenterol Hepatol 2018;30:612-20. [PMID: 29384798 DOI: 10.1097/MEG.0000000000001078] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
222 Schneider AM, Weghuber D, Hetzer B, Entenmann A, Müller T, Zimmermann G, Schütz S, Huber WD, Pichler J. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease. BMC Gastroenterol 2018;18:140. [PMID: 30219028 DOI: 10.1186/s12876-018-0868-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
223 Dragoni G, Le Grazie M, Orlandini B, Rogai F. Golimumab in inflammatory bowel diseases: present and future scenarios. Clin J Gastroenterol 2019;12:1-9. [DOI: 10.1007/s12328-018-0906-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
224 Hanauer S, Panaccione R, Danese S, Cheifetz A, Reinisch W, Higgins PDR, Woodworth DA, Zhang H, Friedman GS, Lawendy N, Quirk D, Nduaka CI, Su C. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019;17:139-147. [PMID: 30012431 DOI: 10.1016/j.cgh.2018.07.009] [Cited by in Crossref: 89] [Cited by in F6Publishing: 74] [Article Influence: 22.3] [Reference Citation Analysis]
225 Kaneider NC, Kaser A. Personalized Treatment in Inflammatory Bowel Disease: For Another Time. Gastroenterology 2018;155:963-4. [PMID: 30201343 DOI: 10.1053/j.gastro.2018.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
226 O’connell J, Rowan C, Stack R, Harkin G, Parihar V, Chan G, Breslin N, Cullen G, Dunne C, Egan L, Harewood G, Leyden J, Maccarthy F, Macmathuna P, Mahmud N, Mckiernan S, Mcnamara D, Mulcahy H, Murray F, O’connor A, O’toole A, Patchett S, Ryan B, Sheridan J, Slattery E, Doherty G, Kevans D. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. European Journal of Gastroenterology & Hepatology 2018;30:1019-26. [DOI: 10.1097/meg.0000000000001177] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
227 Orlandini B, Dragoni G, Variola A, Massella A, Bagnoli S, Campi R, Rogai F. Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real-life experience from two Italian IBD centers. J Dig Dis 2018;19:468-74. [PMID: 30039533 DOI: 10.1111/1751-2980.12648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
228 Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol 2018; 24(32): 3567-3582 [PMID: 30166855 DOI: 10.3748/wjg.v24.i32.3567] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
229 Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G, Sandborn WJ, Danese S, Jairath V, Feagan BG. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients? J Crohns Colitis 2018;12:105-19. [PMID: 28961959 DOI: 10.1093/ecco-jcc/jjx117] [Cited by in Crossref: 43] [Cited by in F6Publishing: 50] [Article Influence: 10.8] [Reference Citation Analysis]
230 Wehkamp J, Stange EF. Recent advances and emerging therapies in the non-surgical management of ulcerative colitis. F1000Res 2018;7:F1000 Faculty Rev-1207. [PMID: 30135722 DOI: 10.12688/f1000research.15159.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
231 Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2018;78:383-94. [PMID: 29332708 DOI: 10.1016/j.jaad.2017.06.043] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
232 Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 2019;80:27-40. [PMID: 30017705 DOI: 10.1016/j.jaad.2018.06.057] [Cited by in Crossref: 134] [Cited by in F6Publishing: 158] [Article Influence: 33.5] [Reference Citation Analysis]
233 Probert CS, Sebastian S, Gaya DR, Hamlin PJ, Gillespie G, Rose A, Tate H, Wheeler C, Irving PM. Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis). BMJ Open Gastroenterol 2018;5:e000212. [PMID: 30002864 DOI: 10.1136/bmjgast-2018-000212] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
234 Reinisch W, Colombel J, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F. Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. Inflammatory Bowel Diseases 2019;25:163-71. [DOI: 10.1093/ibd/izy229] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
235 Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, Siegel CA, Reinisch W, Greenbaum LE. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology 2018;155:1008-1011.e8. [PMID: 29981298 DOI: 10.1053/j.gastro.2018.06.077] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
236 Renna S, Mocciaro F, Ventimiglia M, Orlando R, Macaluso FS, Cappello M, Fries W, Mendolaro M, Privitera AC, Ferracane C, Pisana V, Magnano A, Pluchino D, Inserra G, Scarpulla G, Garufi S, Carroccio A, Siringo S, Di Mitri R, Cottone M, Orlando A. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. Dig Liver Dis 2018;50:1292-8. [PMID: 30007516 DOI: 10.1016/j.dld.2018.06.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
237 Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol 2018;113:1197-205. [PMID: 29925913 DOI: 10.1038/s41395-018-0144-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
238 Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 2018;11:1558-70. [PMID: 29907872 DOI: 10.1038/s41385-018-0050-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 9.8] [Reference Citation Analysis]
239 Hemperly A, Sandborn WJ, Vande Casteele N. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018;24:2527-42. [DOI: 10.1093/ibd/izy189] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
240 Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res 2018;11:215-26. [PMID: 29844695 DOI: 10.2147/JIR.S165330] [Cited by in Crossref: 58] [Cited by in F6Publishing: 68] [Article Influence: 14.5] [Reference Citation Analysis]
241 Bressler B, Williamson M, Sattin B, Camacho F, Steinhart AH. Real World Effectiveness of Golimumab Therapy in Ulcerative Colitis Regardless of Prior TNF Exposure. J Can Assoc Gastroenterol. 2018;1:129-134. [PMID: 31294354 DOI: 10.1093/jcag/gwy019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
242 Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-biroulet L, D’haens G, Sandborn WJ, Feagan BG, Jairath V. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology 2018;16:637-647.e13. [DOI: 10.1016/j.cgh.2017.08.025] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 9.0] [Reference Citation Analysis]
243 Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs 2017;31:299-316. [PMID: 28612180 DOI: 10.1007/s40259-017-0231-8] [Cited by in Crossref: 131] [Cited by in F6Publishing: 155] [Article Influence: 32.8] [Reference Citation Analysis]
244 Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther 2018;47:1578-96. [PMID: 29696670 DOI: 10.1111/apt.14672] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
245 Bae JH, Yang DH. [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics]. Korean J Gastroenterol 2018;71:192-5. [PMID: 29684967 DOI: 10.4166/kjg.2018.71.4.192] [Reference Citation Analysis]
246 Ghattamaneni NKR, Panchal SK, Brown L. Nutraceuticals in rodent models as potential treatments for human Inflammatory Bowel Disease. Pharmacol Res 2018;132:99-107. [PMID: 29680446 DOI: 10.1016/j.phrs.2018.04.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
247 Yamamoto-furusho J, Gutiérrez-grobe Y, López-gómez J, Bosques-padilla F, Rocha-ramírez J. The Mexican consensus on the diagnosis and treatment of ulcerative colitis. Revista de Gastroenterología de México (English Edition) 2018;83:144-67. [DOI: 10.1016/j.rgmxen.2018.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
248 Yamamoto-furusho J, Gutiérrez-grobe Y, López-gómez J, Bosques-padilla F, Rocha-ramírez J. Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. Revista de Gastroenterología de México 2018;83:144-67. [DOI: 10.1016/j.rgmx.2017.08.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
249 Ananthakrishnan AN, Donaldson T, Lasch K, Yajnik V. Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities. Inflamm Bowel Dis. 2017;23:882-893. [PMID: 28375885 DOI: 10.1097/mib.0000000000001099] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
250 Park HJ, Kim J, Saima FT, Rhee KJ, Hwang S, Kim MY, Baik SK, Eom YW, Kim HS. Adipose-derived stem cells ameliorate colitis by suppression of inflammasome formation and regulation of M1-macrophage population through prostaglandin E2. Biochem Biophys Res Commun 2018;498:988-95. [PMID: 29550474 DOI: 10.1016/j.bbrc.2018.03.096] [Cited by in Crossref: 25] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
251 Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A, Hoque S. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016;20:1-326. [PMID: 27220829 DOI: 10.3310/hta20390] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
252 Duijvestein M, Battat R, Vande Casteele N, D’haens GR, Sandborn WJ, Khanna R, Jairath V, Feagan BG. Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Curr Treat Options Gastro 2018;16:129-46. [DOI: 10.1007/s11938-018-0175-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
253 Argollo MC, Kotze PG, Spinelli A, Gomes TN, Danese S. The impact of biologics in surgical outcomes in ulcerative colitis. Best Practice & Research Clinical Gastroenterology 2018;32-33:79-87. [DOI: 10.1016/j.bpg.2018.05.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
254 Pineton de Chambrun G, Tassy B, Kollen L, Dufour G, Valats J, Bismuth M, Funakoshi N, Panaro F, Blanc P. Refractory ulcerative proctitis: How to treat it? Best Practice & Research Clinical Gastroenterology 2018;32-33:49-57. [DOI: 10.1016/j.bpg.2018.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
255 Sorrentino D, Nguyen V, Henderson C, Bankole A. Therapeutic Drug Monitoring and Clinical Outcomes in Immune Mediated Diseases: The Missing Link. Inflamm Bowel Dis. 2016;22:2527-2537. [PMID: 27575494 DOI: 10.1097/mib.0000000000000867] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
256 Ghosh S, Sandborn WJ, Colombel JF, Feagan BG, Panaccione R, Hanauer S, Schreiber S, Peyrin-Biroulet L, Vermeire S, Eichner S, Huang B, Robinson AM, Pappalardo B. Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2016;22:2711-23. [PMID: 27585411 DOI: 10.1097/MIB.0000000000000909] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
257 Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:1756283X17750355. [PMID: 29383030 DOI: 10.1177/1756283x17750355] [Cited by in Crossref: 90] [Cited by in F6Publishing: 104] [Article Influence: 22.5] [Reference Citation Analysis]
258 Olivera P, Sandborn WJ, Panés J, Baumann C, D'Haens G, Vermeire S, Danese S, Peyrin-Biroulet L. Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Aliment Pharmacol Ther 2018;47:773-83. [PMID: 29349829 DOI: 10.1111/apt.14514] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
259 Macaluso FS, Sapienza C, Ventimiglia M, Renna S, Rizzuto G, Orlando R, Di Pisa M, Affronti M, Orlando E, Cottone M, Orlando A. The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study. Inflammatory Bowel Diseases 2018;24:394-401. [DOI: 10.1093/ibd/izx010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
260 Sheridan J, Coe CA, Doran P, Egan L, Cullen G, Kevans D, Leyden J, Galligan M, O'Toole A, McCarthy J, Doherty G. Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772). BMJ Open Gastroenterol 2018;5:e000174. [PMID: 29379609 DOI: 10.1136/bmjgast-2017-000174] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
261 Ogasawara K, Breder CD, Lin DH, Alexander GC. Exposure– and Dose–response Analyses in Dose Selection and Labeling of FDA-approved Biologics. Clinical Therapeutics 2018;40:95-102.e2. [DOI: 10.1016/j.clinthera.2017.11.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
262 Bernstein CN. Does everyone with inflammatory bowel disease need to be treated with combination therapy? Curr Opin Gastroenterol 2016;32:287-93. [PMID: 27115220 DOI: 10.1097/MOG.0000000000000281] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Dave M, Jaiswal P, Cominelli F. Mesenchymal stem/stromal cell therapy for inflammatory bowel disease: an updated review with maintenance of remission. Curr Opin Gastroenterol. 2017;33:59-68. [PMID: 28134690 DOI: 10.1097/mog.0000000000000327] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
264 Greener T, Boland K, Steinhart AH, Silverberg MS. The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn’s Disease. Journal of Crohn's and Colitis 2018;12:458-64. [DOI: 10.1093/ecco-jcc/jjx176] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
265 Renna S, Orlando E, Macaluso FS, Maida M, Affronti M, Giunta M, Sapienza C, Rizzuto G, Orlando R, Dimarco M, Cottone M, Orlando A. Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis. Aliment Pharmacol Ther 2016;44:310-1. [PMID: 27375103 DOI: 10.1111/apt.13692] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
266 Barnes EL, Allegretti JR. Are Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease?: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2016;50:733-741. [PMID: 26535480 DOI: 10.1097/mcg.0000000000000441] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
267 Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:454-465. [PMID: 29205421 DOI: 10.1111/apt.14449] [Cited by in Crossref: 89] [Cited by in F6Publishing: 80] [Article Influence: 17.8] [Reference Citation Analysis]
268 Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:162-175. [PMID: 29205406 DOI: 10.1111/apt.14422] [Cited by in Crossref: 139] [Cited by in F6Publishing: 128] [Article Influence: 27.8] [Reference Citation Analysis]
269 Trigo-Vicente C, Gimeno-Ballester V, Montoiro-Allué R, López-Del Val A. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain. Expert Rev Pharmacoecon Outcomes Res 2018;18:321-9. [PMID: 29192530 DOI: 10.1080/14737167.2018.1411193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
270 Argollo M, Fiorino G, Hindryckx P, Peyrin-biroulet L, Danese S. Novel therapeutic targets for inflammatory bowel disease. Journal of Autoimmunity 2017;85:103-16. [DOI: 10.1016/j.jaut.2017.07.004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 67] [Article Influence: 11.8] [Reference Citation Analysis]
271 Spencer EA, Dubinsky MC. Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Pediatric Clinics of North America 2017;64:1309-26. [DOI: 10.1016/j.pcl.2017.08.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
272 Hyams JS, Chan D, Adedokun OJ, Padgett L, Turner D, Griffiths A, Veereman G, Heyman MB, Rosh JR, Wahbeh G, Strauss R. Subcutaneous Golimumab in Pediatric Ulcerative Colitis: Pharmacokinetics and Clinical Benefit. Inflammatory Bowel Diseases 2017;23:2227-37. [DOI: 10.1097/mib.0000000000001262] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
273 Armuzzi A, Felice C, Lubrano E, Cantini F, Castiglione F, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Marchesoni A, Vecchi M, Olivieri I. Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. Digestive and Liver Disease 2017;49:1298-305. [DOI: 10.1016/j.dld.2017.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
274 Limdi JK. Golimumab for ulcerative colitis: adding perspective to the pursuit. Frontline Gastroenterol. 2018;9:232-233. [PMID: 30047548 DOI: 10.1136/flgastro-2017-100929] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
275 Russi L, Scharl M, Rogler G, Biedermann L. The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series. Inflamm Intest Dis 2017;2:131-8. [PMID: 30018964 DOI: 10.1159/000481400] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
276 Martineau C, Flourié B, Wils P, Vaysse T, Altwegg R, Buisson A, Amiot A, Pineton de Chambrun G, Abitbol V, Fumery M, Hébuterne X, Viennot S, Laharie D, Beaugerie L, Nancey S, Sokol H; the Goli-Crohn Study Group. Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. Aliment Pharmacol Ther 2017;46:1077-84. [DOI: 10.1111/apt.14371] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
277 Samaan MA, Pavlidis P, Digby-Bell J, Johnston EL, Dhillon A, Paramsothy R, Akintimehin AO, Medcalf L, Chung-Faye G, DuBois P, Koumoutsos I, Powell N, Anderson SHC, Sanderson J, Hayee BH, Irving PM. Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres. Frontline Gastroenterol. 2018;9:221-231. [PMID: 30047549 DOI: 10.1136/flgastro-2017-100895] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
278 Cross RK. Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:1689-701. [DOI: 10.1097/mib.0000000000001261] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
279 Holleran G, Lopetuso L, Petito V, Graziani C, Ianiro G, McNamara D, Gasbarrini A, Scaldaferri F. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. Int J Mol Sci. 2017;18. [PMID: 28934123 DOI: 10.3390/ijms18102020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
280 Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 26] [Article Influence: 7.2] [Reference Citation Analysis]
281 Dudley-Brown S. Optimizing Inflammatory Bowel Disease Management: An Overview for the Gastroenterology Nurse. Gastroenterol Nurs 2017;40 Suppl 1S:S1-S14. [PMID: 27922458 DOI: 10.1097/SGA.0000000000000277] [Reference Citation Analysis]
282 Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, Papa A. Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci 2017;18:E1973. [PMID: 28906475 DOI: 10.3390/ijms18091973] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
283 Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev 2017;9:CD011572. [PMID: 28886205 DOI: 10.1002/14651858.CD011572.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
284 Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol 2017;10:773-90. [PMID: 29051788 DOI: 10.1177/1756283X17727388] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
285 Tappenden P, Ren S, Archer R, Harvey R, James MM, Basarir H, Stevens J, Lobo A, Hoque S. A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. Pharmacoeconomics 2016;34:1023-38. [PMID: 27125898 DOI: 10.1007/s40273-016-0409-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
286 Stern S, Ward AJ, Saint-laurent Thibault C, Camacho F, Rahme E, Naessens D, Aumais G, Bernard E, Bourdages R, Cohen A, Pare P, Dyrda P. Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation. Journal of Medical Economics 2018;21:27-37. [DOI: 10.1080/13696998.2017.1371033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
287 Qiu Y, Mao R, Chen B, Zhang S, Guo J, He Y, Zeng Z, Ben-horin S, Chen M. Effects of Combination Therapy With Immunomodulators on Trough Levels and Antibodies Against Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Meta-analysis. Clinical Gastroenterology and Hepatology 2017;15:1359-1372.e6. [DOI: 10.1016/j.cgh.2017.02.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 6.6] [Reference Citation Analysis]
288 Lee Y, Choo J, Kim SJ, Heo G, Pothoulakis C, Kim YH, Im E. Analysis of endogenous lipids during intestinal wound healing. PLoS One 2017;12:e0183028. [PMID: 28800645 DOI: 10.1371/journal.pone.0183028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
289 Taxonera C, Rodríguez C, Bertoletti F, Menchén L, Arribas J, Sierra M, Arias L, Martínez-montiel P, Juan A, Iglesias E, Algaba A, Manceñido N, Rivero M, Barreiro-de Acosta M, López-serrano P, Argüelles-arias F, Gutierrez A, Busquets D, Gisbert JP, Olivares D, Calvo M, Alba C. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:1394-402. [DOI: 10.1097/mib.0000000000001144] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 10.2] [Reference Citation Analysis]
290 Peyrin-biroulet L, Van Assche G, Armuzzi A, Garcia-alvarez L, Lara N, Black CM, Khalifa A, Cornillie F, Kachroo S. Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2017;15:1154-1161.e1. [DOI: 10.1016/j.cgh.2016.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
291 Sofia MA, Rubin DT. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci 2017;62:833-42. [PMID: 28197743 DOI: 10.1007/s10620-017-4479-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
292 Ferrante M, de Buck van Overstraeten A, Schils N, Moens A, Van Assche G, Wolthuis A, Vermeire S, D’hoore A. Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy. Journal of Crohn's and Colitis 2017;11:1353-61. [DOI: 10.1093/ecco-jcc/jjx095] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
293 Cameron C, Ewara E, Wilson FR, Varu A, Dyrda P, Hutton B, Ingham M. The Importance of Considering Differences in Study Design in Network Meta-analysis: An Application Using Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis. Med Decis Making 2017;37:894-904. [DOI: 10.1177/0272989x17711933] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
294 Stawowczyk E, Kawalec P. Cost-effectiveness of biological treatment of ulcerative colitis - a systematic review. Prz Gastroenterol 2017;12:90-7. [PMID: 28702096 DOI: 10.5114/pg.2017.68166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
295 D'Haens G. Standardisation of Study Protocols - Pros and Cons. J Crohns Colitis 2016;10 Suppl 2:S553-9. [PMID: 27604980 DOI: 10.1093/ecco-jcc/jjw001] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
296 Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther 2017;17:879-86. [PMID: 28472597 DOI: 10.1080/14712598.2017.1327576] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
297 Kokkinidis DG, Bosdelekidou EE, Iliopoulou SM, Tassos AG, Texakalidis PT, Economopoulos KP, Kousoulis AA. Emerging treatments for ulcerative colitis: a systematic review. Scand J Gastroenterol 2017;52:923-31. [PMID: 28503977 DOI: 10.1080/00365521.2017.1326163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
298 Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 2017;129:538-53. [DOI: 10.1080/00325481.2017.1319730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
299 Boal Carvalho P, Cotter J. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. Drugs. 2017;77:159-173. [PMID: 28078646 DOI: 10.1007/s40265-016-0676-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 56] [Article Influence: 7.8] [Reference Citation Analysis]
300 West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE, Keshav S, Travis SPL, Powrie F; Oxford IBD Cohort Investigators. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med 2017;23:579-89. [PMID: 28368383 DOI: 10.1038/nm.4307] [Cited by in Crossref: 259] [Cited by in F6Publishing: 318] [Article Influence: 51.8] [Reference Citation Analysis]
301 Vande Casteele N, Khanna R. Therapeutic Drug Monitoring of Golimumab in the Treatment of Ulcerative Colitis. Pharm Res 2017;34:1556-63. [PMID: 28374338 DOI: 10.1007/s11095-017-2150-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
302 Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D’incà R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzziello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Aratari A, Bossa F, Cappello M, Cassinotti A, Chiriatti A, Fiorino G, Formica V, Guidi L, Losco A, Mocciaro F, Onali S, Pastorelli L, Pica R, Principi M, Renna S, Ricci C, Rispo A, Rogai F, Sarmati L, Scaldaferri F, Spina L, Tambasco R, Testa A, Viscido A. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease 2017;49:338-58. [DOI: 10.1016/j.dld.2017.01.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
303 Sparrow MP. Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target. Expert Opin Biol Ther 2017;17:613-21. [PMID: 28316250 DOI: 10.1080/14712598.2017.1309390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
304 Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease: Biologics therapy in East Asia. Journal of Gastroenterology and Hepatology 2017;32:769-77. [DOI: 10.1111/jgh.13612] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
305 Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45:1291-1302. [PMID: 28326566 DOI: 10.1111/apt.14030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 158] [Article Influence: 34.4] [Reference Citation Analysis]
306 Hibi T, Imai Y, Senoo A, Ohta K, Ukyo Y. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study). J Gastroenterol 2017;52:1101-11. [PMID: 28324167 DOI: 10.1007/s00535-017-1326-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
307 Fiorino G, Bonovas S, Cicerone C, Allocca M, Furfaro F, Correale C, Danese S. The safety of biological pharmacotherapy for the treatment of ulcerative colitis. Expert Opin Drug Saf. 2017;16:437-443. [PMID: 28279079 DOI: 10.1080/14740338.2017.1298743] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
308 Strik AS, Berends SE, Mathôt RA, D'Haens GR, Löwenberg M. Golimumab for moderate to severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2017;11:401-6. [PMID: 28276288 DOI: 10.1080/17474124.2017.1303376] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
309 Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ 2018;19:229-40. [PMID: 28271250 DOI: 10.1007/s10198-017-0879-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
310 Atreya R, Neurath MF. Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease. Visc Med. 2017;33:82-88. [PMID: 28612022 DOI: 10.1159/000458006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
311 Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut 2017;66:199-209. [PMID: 27856614 DOI: 10.1136/gutjnl-2016-312912] [Cited by in Crossref: 77] [Cited by in F6Publishing: 70] [Article Influence: 15.4] [Reference Citation Analysis]
312 Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269-278. [PMID: 28144028 DOI: 10.1038/nrgastro.2016.208] [Cited by in Crossref: 287] [Cited by in F6Publishing: 267] [Article Influence: 57.4] [Reference Citation Analysis]
313 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
314 Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 566] [Article Influence: 98.4] [Reference Citation Analysis]
315 Di Narzo AF, Telesco SE, Brodmerkel C, Argmann C, Peters LA, Li K, Kidd B, Dudley J, Cho J, Schadt EE, Kasarskis A, Dobrin R, Hao K. High-Throughput Characterization of Blood Serum Proteomics of IBD Patients with Respect to Aging and Genetic Factors. PLoS Genet. 2017;13:e1006565. [PMID: 28129359 DOI: 10.1371/journal.pgen.1006565] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
316 Aggarwal A, Sabol T, Vaziri H. Update on the Use of Biologic Therapy in Ulcerative Colitis. Curr Treat Options Gastroenterol 2017;15:155-67. [PMID: 28120279 DOI: 10.1007/s11938-017-0120-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
317 Amezaga AJ, Van Assche G. Practical Approaches to "Top-Down" Therapies for Crohn's Disease. Curr Gastroenterol Rep 2016;18:35. [PMID: 27184044 DOI: 10.1007/s11894-016-0507-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
318 Rodríguez-lago I, Gómez-irwin L, Fernández E, Higuera R, Cabriada JL. Granulocyte-Monocyte Apheresis as an Adjuvant Therapy to Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis: Granulocyte-Monocyte Apheresis After Anti-TNF Failure. Ther Apher Dial 2017;21:26-30. [DOI: 10.1111/1744-9987.12485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
319 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
320 Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:998-1009. [PMID: 26835982 DOI: 10.1097/MIB.0000000000000661] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
321 Bosca-Watts MM, Cortes X, Iborra M, Huguet JM, Sempere L, Garcia G, Gil R, Garcia M, Muñoz M, Almela P, Maroto N, Paredes JM. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. World J Gastroenterol 2016; 22(47): 10432-10439 [PMID: 28058024 DOI: 10.3748/wjg.v22.i47.10432] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
322 Macaluso FS, Renna S, Orlando A, Cottone M. The biologics of ulcerative colitis. Expert Opinion on Biological Therapy 2016;17:175-84. [DOI: 10.1080/14712598.2017.1271871] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
323 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 381] [Article Influence: 138.3] [Reference Citation Analysis]
324 Harzallah I, Rigaill J, Williet N, Paul S, Roblin X. Golimumab pharmacokinetics in ulcerative colitis: a literature review. Therap Adv Gastroenterol 2017;10:89-100. [PMID: 28286562 DOI: 10.1177/1756283X16676194] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
325 Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol 2016; 22(42): 9300-9313 [PMID: 27895418 DOI: 10.3748/wjg.v22.i42.9300] [Cited by in CrossRef: 119] [Cited by in F6Publishing: 104] [Article Influence: 19.8] [Reference Citation Analysis]
326 Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141-150. [PMID: 27832357 DOI: 10.1007/s00535-016-1283-0] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 7.7] [Reference Citation Analysis]
327 Tsai HH, Black C. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis. Expert Rev Pharmacoecon Outcomes Res 2016;16:679-83. [PMID: 27726457 DOI: 10.1080/14737167.2016.1246186] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
328 Vickers AD, Ainsworth C, Mody R, Bergman A, Ling CS, Medjedovic J, Smyth M. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. PLoS One. 2016;11:e0165435. [PMID: 27776175 DOI: 10.1371/journal.pone.0165435] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 9.7] [Reference Citation Analysis]
329 McConnell RA, Mahadevan U. Use of Immunomodulators and Biologics Before, During, and After Pregnancy. Inflamm Bowel Dis. 2016;22:213-223. [PMID: 26444103 DOI: 10.1097/mib.0000000000000596] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
330 Panes J, Jairath V, Levesque BG. Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases. Gastroenterology. 2017;152:362-373.e3. [PMID: 27751880 DOI: 10.1053/j.gastro.2016.10.005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 8.2] [Reference Citation Analysis]
331 Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol 2017;13:223-33. [PMID: 27687496 DOI: 10.1080/1744666X.2017.1243468] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
332 Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, Hampe J, Hartmann F, Neurath MF, Maul J, Preiss JC, Schmelz R, Siegmund B, Schulze H, Teich N, von Arnim U, Baumgart DC, Schmidt C. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Aliment Pharmacol Ther. 2016;44:1199-1212. [PMID: 27714831 DOI: 10.1111/apt.13813] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 18.8] [Reference Citation Analysis]
333 Naganuma M, Mizuno S, Nanki K, Sugimoto S, Kanai T. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol 2016;9:329-36. [DOI: 10.1007/s12328-016-0686-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
334 Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clin Gastroenterol Hepatol. 2017;15:229-239.e5. [PMID: 27639327 DOI: 10.1016/j.cgh.2016.08.044] [Cited by in Crossref: 114] [Cited by in F6Publishing: 104] [Article Influence: 19.0] [Reference Citation Analysis]
335 Merras-salmio L, Kolho K. Golimumab Therapy in Six Patients With Severe Pediatric Onset Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2016;63:344-7. [DOI: 10.1097/mpg.0000000000001165] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
336 Díaz-Jiménez D, De la Fuente M, Dubois-Camacho K, Landskron G, Fuentes J, Pérez T, González MJ, Simian D, Hermoso MA, Quera R. Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution. BMC Gastroenterol 2016;16:103. [PMID: 27565556 DOI: 10.1186/s12876-016-0520-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
337 Kedia S, Ahuja V, Makharia GK. Golimumab for moderately to severely active ulcerative colitis. Expert Rev Clin Pharmacol 2016;9:1273-82. [PMID: 27498886 DOI: 10.1080/17512433.2016.1221759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
338 Dave M, Mehta K, Luther J, Baruah A, Dietz AB, Faubion WA. Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015;21:2696-2707. [PMID: 26230863 DOI: 10.1097/mib.0000000000000543] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 10.7] [Reference Citation Analysis]
339 Stawowczyk E, Kawalec P, Pilc A. Cost-Effectiveness Analysis of 1-Year Treatment with Golimumab/Standard Care and Standard Care Alone for Ulcerative Colitis in Poland. PLoS One 2016;11:e0160444. [PMID: 27494322 DOI: 10.1371/journal.pone.0160444] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
340 Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies: . Inflammatory Bowel Diseases 2016;22:1999-2015. [DOI: 10.1097/mib.0000000000000772] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 12.3] [Reference Citation Analysis]
341 Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis. 2017;11:35-46. [PMID: 27440869 DOI: 10.1093/ecco-jcc/jjw133] [Cited by in Crossref: 68] [Cited by in F6Publishing: 76] [Article Influence: 11.3] [Reference Citation Analysis]
342 Moćko P, Kawalec P, Pilc A. Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis. Pharmacotherapy 2016;36:870-9. [PMID: 27312826 DOI: 10.1002/phar.1785] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
343 Song YD, Liu SX, Zhong YQ. Biological agents for treatment of inflammatory bowel disease: Research progress and associated risks. Shijie Huaren Xiaohua Zazhi 2016; 24(19): 2964-2973 [DOI: 10.11569/wcjd.v24.i19.2964] [Reference Citation Analysis]
344 Pagnini C, Menasci F, Desideri F, Corleto VD, Delle Fave G, Di Giulio E. Endoscopic scores for inflammatory bowel disease in the era of ‘mucosal healing’: Old problem, new perspectives. Digestive and Liver Disease 2016;48:703-8. [DOI: 10.1016/j.dld.2016.03.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
345 Drabik A, Sturm A, Blömacher M, Helwig U. Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study. JMIR Res Protoc 2016;5:e124. [PMID: 27352964 DOI: 10.2196/resprot.5791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
346 Tursi A, Allegretta L, Della Valle N, Hadad Y, Penna A, Pranzo G, Ricciardelli C, Paiano P, Picchio M. Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis. Clin Res Hepatol Gastroenterol 2016;40:e61-3. [PMID: 27297910 DOI: 10.1016/j.clinre.2016.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
347 Iskandar HN, Dhere T, Farraye FA. Ulcerative Colitis: Update on Medical Management. Curr Gastroenterol Rep. 2015;17:44. [PMID: 26386686 DOI: 10.1007/s11894-015-0466-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
348 Tursi A, Della Valle N, Penna A, Pranzo G, Ricciardelli C, Picchio M. Letter: effectiveness of golimumab to induce remission in outpatient ulcerative colitis in Italy. Aliment Pharmacol Ther 2016;43:657-8. [PMID: 26843348 DOI: 10.1111/apt.13509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
349 Samaan MA, Irving PM. The impact of updated NICE guidelines on biologic treatment of ulcerative colitis: reflections on past practices, the changing present and implications for the future. Expert Opin Biol Ther 2016;16:975-7. [PMID: 27186809 DOI: 10.1080/14712598.2016.1189529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
350 Chaparro M, Gisbert JP. Maintenance therapy options for ulcerative colitis. Expert Opinion on Pharmacotherapy 2016;17:1339-49. [DOI: 10.1080/14656566.2016.1187132] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
351 Ferrari L, Krane MK, Fichera A. Inflammatory bowel disease surgery in the biologic era. World J Gastrointest Surg 2016; 8(5): 363-370 [PMID: 27231514 DOI: 10.4240/wjgs.v8.i5.363] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
352 Chen J, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TWT, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-smith G, Lawrance IC, Mclachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther 2016;44:127-44. [DOI: 10.1111/apt.13670] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
353 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
354 Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1385-1397. e10. [PMID: 27189910 DOI: 10.1016/j.cgh.2016.04.039] [Cited by in Crossref: 216] [Cited by in F6Publishing: 192] [Article Influence: 36.0] [Reference Citation Analysis]
355 Chen F, Yan CK. Recent progress in drug therapy of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2016; 24(12): 1840-1845 [DOI: 10.11569/wcjd.v24.i12.1840] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
356 Gibson PR, Feagan BG, Sandborn WJ, Marano C, Strauss R, Johanns J, Padgett L, Collins J, Tarabar D, Hebzda Z, Rutgeerts P, Reinisch W. Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year. Clin Transl Gastroenterol 2016;7:e168. [PMID: 27124701 DOI: 10.1038/ctg.2016.24] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
357 McLean LP, Cross RK. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis. Expert Opin Drug Metab Toxicol 2016;12:833-42. [PMID: 27096357 DOI: 10.1080/17425255.2016.1181171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
358 Saigusa K, Matsuoka K, Sugimoto S, Arai M, Kiyohara H, Takeshita K, Mizuno S, Mori K, Nanki K, Takeshita T, Nakazato Y, Yajima T, Naganuma M, Hisamatsu T, Ogata H, Iwao Y, Kanai T. Ulcerative colitis endoscopic index of severity is associated with long‐term prognosis in ulcerative colitis patients treated with infliximab. Digestive Endoscopy 2016;28:665-70. [DOI: 10.1111/den.12655] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
359 Sofia MA, Rubin DT. Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therap Adv Gastroenterol 2016;9:548-59. [PMID: 27366223 DOI: 10.1177/1756283X16643242] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
360 Jauregui-Amezaga A, Vermeire S, Prenen H. Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer. Ann Gastroenterol 2016;29:127-36. [PMID: 27065724 DOI: 10.20524/aog.2016.0004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
361 López-ibáñez M, Marín-jiménez I. Niveles de fármaco y anticuerpos antifármaco en el manejo clínico del paciente con enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2016;39:265-72. [DOI: 10.1016/j.gastrohep.2015.09.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
362 Vallabhaneni S, Chiller TM. Fungal Infections and New Biologic Therapies. Curr Rheumatol Rep 2016;18. [DOI: 10.1007/s11926-016-0572-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 8.5] [Reference Citation Analysis]
363 Ungar B, Kopylov U. Advances in the development of new biologics in inflammatory bowel disease. Ann Gastroenterol. 2016;29:243-248. [PMID: 27366024 DOI: 10.20524/aog.2016.0027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
364 Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol 2015;27:804-12. [PMID: 25933126 DOI: 10.1097/MEG.0000000000000378] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
365 Grinspan A, Kornbluth A. Positioning Therapy for Ulcerative Colitis. Curr Gastroenterol Rep 2015;17:29. [PMID: 26143627 DOI: 10.1007/s11894-015-0454-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
366 Kawalec P, Pilc A. An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Arch Med Sci 2016;12:1097-109. [PMID: 27695502 DOI: 10.5114/aoms.2016.58682] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
367 Calvo-Río V, Blanco R, Santos-Gómez M, Rubio-Romero E, Cordero-Coma M, Gallego-Flores A, Veroz R, Torre I, Hernández FF, Atanes A, Loricera J, González-Vela MC, Palmou N, Hernández JL, González-Gay MA. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum 2016;46:95-101. [PMID: 27060872 DOI: 10.1016/j.semarthrit.2016.03.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 8.5] [Reference Citation Analysis]
368 Scott FI, Lichtenstein GR. Advances in Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease: 2015 in Review. Curr Treat Options Gastroenterol 2016;14:91-102. [PMID: 26847358 DOI: 10.1007/s11938-016-0085-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
369 Petkau JM, Eksteen B. Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab. Biologics 2016;10:33-52. [PMID: 27022240 DOI: 10.2147/BTT.S71679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
370 Shahidi N, Bressler B, Panaccione R. The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis.Therap Adv Gastroenterol. 2016;9:330-338. [PMID: 27134663 DOI: 10.1177/1756283X16635081] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
371 Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol 2016; 7(1): 1-16 [PMID: 26909224 DOI: 10.4291/wjgp.v7.i1.1] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
372 Pugliese D, Felice C, Landi R, Papa A, Guidi L, Armuzzi A. Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug Healthc Patient Saf. 2016;8:1-7. [PMID: 26893582 DOI: 10.2147/dhps.s62649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
373 Van Assche G, Peyrin-Biroulet L, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-Farreras S, Fan T, Ding Q, Black CM, Kachroo S. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study. Dig Liver Dis. 2016;48:592-600. [PMID: 26935454 DOI: 10.1016/j.dld.2016.01.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
374 Strik AS, Bots SJA, D’haens G, Löwenberg M. Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. Expert Review of Clinical Pharmacology 2015;9:429-39. [DOI: 10.1586/17512433.2016.1133288] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
375 Löwenberg M, D’Haens G. Next-Generation Therapeutics for IBD. Curr Gastroenterol Rep. 2015;17:21. [PMID: 26031830 DOI: 10.1007/s11894-015-0444-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
376 Berns M, Hommes DW. Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future. Expert Opinion on Investigational Drugs 2016;25:129-43. [DOI: 10.1517/13543784.2016.1126247] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
377 Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016;10:607-618. [PMID: 26746169 DOI: 10.1093/ecco-jcc/jjw004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
378 Detrez I, Dreesen E, Van Stappen T, de Vries A, Brouwers E, Van Assche G, Vermeire S, Ferrante M, Gils A. Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis. J Crohns Colitis. 2016;10:575-581. [PMID: 26738756 DOI: 10.1093/ecco-jcc/jjv241] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 8.8] [Reference Citation Analysis]
379 Abdel Hadi L, Di Vito C, Riboni L. Fostering Inflammatory Bowel Disease: Sphingolipid Strategies to Join Forces. Mediators Inflamm 2016;2016:3827684. [PMID: 26880864 DOI: 10.1155/2016/3827684] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 5.2] [Reference Citation Analysis]
380 Moon W. Golimumab Therapy in Ulcerative Colitis. Korean J Gastroenterol 2016;67:64. [DOI: 10.4166/kjg.2016.67.2.64] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
381 Alexakis C, Pollok RCG. Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis. World J Gastrointest Surg 2015; 7(12): 360-369 [PMID: 26730281 DOI: 10.4240/wjgs.v7.i12.360] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
382 Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy 2015;35:412-23. [PMID: 25884529 DOI: 10.1002/phar.1561] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
383 Shahidi N, Bressler B, Panaccione R. Vedolizumab for the treatment of ulcerative colitis. Expert Opinion on Biological Therapy 2015;16:129-35. [DOI: 10.1517/14712598.2016.1121231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
384 Chaparro M, Gisbert JP. [New molecules in the treatment of inflammatory bowel disease]. Gastroenterol Hepatol 2016;39:411-23. [PMID: 26631943 DOI: 10.1016/j.gastrohep.2015.09.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
385 Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y, Ogino H. Promising biological therapies for ulcerative colitis: A review of the literature. World J Gastrointest Pathophysiol 2015; 6(4): 219-227 [PMID: 26600980 DOI: 10.4291/wjgp.v6.i4.219] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
386 Khan HM, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol. 2015;8:293-302. [PMID: 26648749 DOI: 10.2147/ceg.s57248] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
387 Trivedi I, Hanauer SB. Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. Expert Opin Drug Saf 2015;14:1915-34. [PMID: 26559664 DOI: 10.1517/14740338.2015.1108961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
388 Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice. J Clin Pharmacol. 2015;55 Suppl 3:S39-S50. [PMID: 25707962 DOI: 10.1002/jcph.374] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 9.1] [Reference Citation Analysis]
389 Demir AK, Demirtas A, Kaya SU, Tastan I, Butun I, Sagcan M, Sahin S, Tasliyurt T, Yilmaz A. The relationship between the neutrophil-lymphocyte ratio and disease activity in patients with ulcerative colitis. Kaohsiung J Med Sci 2015;31:585-90. [PMID: 26678939 DOI: 10.1016/j.kjms.2015.10.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
390 Bootz F, Neri D. Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. Drug Discov Today 2016;21:180-9. [PMID: 26526566 DOI: 10.1016/j.drudis.2015.10.012] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 6.6] [Reference Citation Analysis]
391 Essat M, Tappenden P, Ren S, Bessey A, Archer R, Wong R, Lobo A, Hoque S. Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics 2016;34:245-57. [DOI: 10.1007/s40273-015-0334-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
392 Schreiber S. [Anti-TNF biosimilars in chronic inflammatory bowel disease. What can rheumatologists learn from it?]. Z Rheumatol 2015;74:689-94. [PMID: 26450434 DOI: 10.1007/s00393-014-1488-7] [Reference Citation Analysis]
393 Lopez-sanroman A. The Concept of Mucosal Healing in Ulcerative Colitis: Time and Reasons for a Reappraisal. ECCOJC 2015;10:3-4. [DOI: 10.1093/ecco-jcc/jjv183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
394 Pan WJ, Köck K, Rees WA, Sullivan BA, Evangelista CM, Yen M, Andrews JM, Radford-Smith GL, Prince PJ, Reynhardt KO. Clinical pharmacology of AMG 181, a gut-specific human anti-α4β7 monoclonal antibody, for treating inflammatory bowel diseases. Br J Clin Pharmacol. 2014;78:1315-1333. [PMID: 24803302 DOI: 10.1111/bcp.12418] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
395 De Wilde K, Debusschere K, Beeckman S, Jacques P, Elewaut D. Integrating the pathogenesis of spondyloarthritis: gut and joint united? Curr Opin Rheumatol 2015;27:189-96. [PMID: 25588139 DOI: 10.1097/BOR.0000000000000144] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
396 LeBlanc K, Mosli MH, Parker CE, MacDonald JK. The impact of biological interventions for ulcerative colitis on health-related quality of life. Cochrane Database Syst Rev. 2015;CD008655. [PMID: 26393522 DOI: 10.1002/14651858.cd008655.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
397 Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol. 2015;50:74-80. [PMID: 25523558 DOI: 10.3109/00365521.2014.987809] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 9.4] [Reference Citation Analysis]
398 Bravatà I, Fiorino G, Allocca M, Repici A, Danese S. New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease. Scand J Gastroenterol 2015;50:113-20. [PMID: 25523561 DOI: 10.3109/00365521.2014.993700] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
399 Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Vande Casteele N. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21:182-197. [PMID: 25222660 DOI: 10.1097/mib.0000000000000202] [Cited by in Crossref: 118] [Cited by in F6Publishing: 113] [Article Influence: 16.9] [Reference Citation Analysis]
400 Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. Gut Liver 2015;9:18-27. [PMID: 25547087 DOI: 10.5009/gnl14226] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 10.1] [Reference Citation Analysis]
401 Sandborn WJ, Panés J, Zhang H, Yu D, Niezychowski W, Su C. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology 2016;150:96-102. [PMID: 26376350 DOI: 10.1053/j.gastro.2015.09.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 8.9] [Reference Citation Analysis]
402 Alten R. [Biosimilars in rheumatology. Development and results of clinical trials]. Z Rheumatol 2015;74:682-8. [PMID: 26347121 DOI: 10.1007/s00393-014-1487-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
403 Barreiro-de Acosta M, Vallejo N, de la Iglesia D, Uribarri L, Bastón I, Ferreiro-Iglesias R, Lorenzo A, Domínguez-Muñoz JE. Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. J Crohns Colitis 2016;10:13-9. [PMID: 26351390 DOI: 10.1093/ecco-jcc/jjv158] [Cited by in Crossref: 92] [Cited by in F6Publishing: 104] [Article Influence: 13.1] [Reference Citation Analysis]
404 Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol 2015;8:257-69. [PMID: 26316792 DOI: 10.2147/CEG.S58152] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
405 Rogler G. Where are we heading to in pharmacological IBD therapy? Pharmacol Res. 2015;100:220-227. [PMID: 26277232 DOI: 10.1016/j.phrs.2015.07.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
406 Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786 [PMID: 26269667 DOI: 10.3748/wjg.v21.i29.8776] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
407 de Mattos BR, Garcia MP, Nogueira JB, Paiatto LN, Albuquerque CG, Souza CL, Fernandes LG, Tamashiro WM, Simioni PU. Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. Mediators Inflamm. 2015;2015:493012. [PMID: 26339135 DOI: 10.1155/2015/493012] [Cited by in Crossref: 83] [Cited by in F6Publishing: 93] [Article Influence: 11.9] [Reference Citation Analysis]
408 Bernstein CN. Spicing up the Treatment of Mild to Moderate Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2015;13:1450-2. [DOI: 10.1016/j.cgh.2015.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
409 Mir Viladrich I, Daudén Tello E, Solano-López G, López Longo FJ, Taxonera Samso C, Sánchez Martínez P, Martínez Lacasa X, García Gasalla M, Dorca Sargatal J, Arias-Guillén M, García García JM. Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment. Arch Bronconeumol 2016;52:36-45. [PMID: 26187708 DOI: 10.1016/j.arbres.2015.04.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 3.9] [Reference Citation Analysis]
410 Peng JC, Shen J, Ran ZH. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease. J Dig Dis. 2014;15:585-590. [PMID: 25251263 DOI: 10.1111/1751-2980.12193] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
411 Lam MC, Bressler B. Vedolizumab for ulcerative colitis and Crohn’s disease: results and implications of GEMINI studies. Immunotherapy. 2014;6:963-971. [PMID: 25341118 DOI: 10.2217/imt.14.66] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
412 Łodyga M, Eder P, Bartnik W, Gonciarz M, Kłopocka M, Linke K, Małecka-Panas E, Radwan P, Rydzewska G. New pharmaceuticals in inflammatory bowel disease. Prz Gastroenterol 2015;10:57-60. [PMID: 26557934 DOI: 10.5114/pg.2015.52702] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
413 Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Zhang H, Colombel JF. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015;42:504-514. [PMID: 26119226 DOI: 10.1111/apt.13291] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 6.7] [Reference Citation Analysis]
414 Lobatón T, Bessissow T, De Hertogh G, Lemmens B, Maedler C, Van Assche G, Vermeire S, Bisschops R, Rutgeerts P, Bitton A. The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. J Crohns Colitis. 2015;9:846-852. [PMID: 26116558 DOI: 10.1093/ecco-jcc/jjv111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
415 Seo GS, Chae SC. Biological therapy for ulcerative colitis: An update. World J Gastroenterol. 2014;20:13234-13238. [PMID: 25309060 DOI: 10.3748/wjg.v20.i37] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
416 Yamada S, Yoshino T, Matsuura M, Kimura M, Koshikawa Y, Minami N, Toyonaga T, Honzawa Y, Nakase H. Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis. Intest Res 2015;13:250-8. [PMID: 26131000 DOI: 10.5217/ir.2015.13.3.250] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
417 Cohen R, Skup M, Ozbay AB, Rizzo J, Yang M, Diener M, Chao J. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. J Med Econ 2015;18:447-56. [PMID: 25728698 DOI: 10.3111/13696998.2015.1021353] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
418 Alten R, Cronstein BN. Clinical trial development for biosimilars. Seminars in Arthritis and Rheumatism 2015;44:S2-8. [DOI: 10.1016/j.semarthrit.2015.04.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
419 Quetglas EG, Armuzzi A, Wigge S, Fiorino G, Barnscheid L, Froelich M, Danese S. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. Eur J Clin Pharmacol 2015;71:773-99. [PMID: 26008212 DOI: 10.1007/s00228-015-1862-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
420 Mei WQ, Hu HZ, Liu Y, Li ZC, Wang WG. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: A meta-analysis. World J Gastroenterol 2015; 21(19): 6044-6051 [PMID: 26019471 DOI: 10.3748/wjg.v21.i19.6044] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
421 Jones J, Peña-Sánchez JN. Who should receive biologic therapy for IBD?: The rationale for the application of a personalized approach. Gastroenterol Clin North Am 2014;43:425-40. [PMID: 25110251 DOI: 10.1016/j.gtc.2014.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
422 Felice C, Marzo M, Pugliese D, Papa A, Rapaccini GL, Guidi L, Armuzzi A. Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases. Expert Opinion on Biological Therapy 2015;15:1107-17. [DOI: 10.1517/14712598.2015.1044434] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
423 Zheng K, Zhang S, Wang C, Zhao W, Shen H. Health-related quality of life in Chinese patients with mild and moderately active ulcerative colitis. PLoS One 2015;10:e0124211. [PMID: 25915777 DOI: 10.1371/journal.pone.0124211] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
424 Hindryckx P, Baert F, Hart A, Magro F, Armuzzi A, Peyrin-biroulet L; the Clinical Trial Committee Clincom of the European Crohn’s and Colitis Organisation (ECCO). Clinical Trials in Ulcerative Colitis: A Historical Perspective. ECCOJC 2015;9:580-8. [DOI: 10.1093/ecco-jcc/jjv074] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
425 Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2015;41:1094-1103. [PMID: 25809869 DOI: 10.1111/apt.13175] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 9.7] [Reference Citation Analysis]
426 Baki E, Zwickel P, Zawierucha A, Ehehalt R, Gotthardt D, Stremmel W, Gauss A. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. World J Gastroenterol 2015; 21(11): 3282-3290 [PMID: 25805935 DOI: 10.3748/wjg.v21.i11.3282] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
427 Thorlund K, Druyts E, Toor K, Mills EJ. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol 2015;9:693-700. [PMID: 25763862 DOI: 10.1586/17474124.2015.1024657] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
428 Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058.e3. [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 220] [Article Influence: 30.1] [Reference Citation Analysis]
429 Rutka M, Milassin Á, Szepes Z, SzŰcs M, Nyári T, Bálint A, Bor R, Molnár T, Farkas K. Is mucosal healing more common than clinical remission in ulcerative colitis? - Is it the truth or only a myth coming from the studies? Scand J Gastroenterol 2015;50:985-90. [PMID: 25733077 DOI: 10.3109/00365521.2015.1018313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
430 Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015;8:66-82. [PMID: 25729432 DOI: 10.1177/1756283x14558193] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 12.7] [Reference Citation Analysis]
431 Song Y, Zheng P. Efficacy and safety of tumor necrosis factor-α blockers for ulcerative colitis: A systematic review and meta-analysis of published randomized controlled trials. Journal of Food and Drug Analysis 2015;23:1-10. [DOI: 10.1016/j.jfda.2014.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
432 Lawrance IC. Early investigational TNF receptor antagonists for the treatment of ulcerative colitis. Expert Opin Investig Drugs 2015;24:761-8. [PMID: 25719407 DOI: 10.1517/13543784.2015.1020371] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
433 Siebert S, Tsoukas A, Robertson J, Mcinnes I, Touyz RM. Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases. Pharmacol Rev 2015;67:280-309. [DOI: 10.1124/pr.114.009639] [Cited by in Crossref: 196] [Cited by in F6Publishing: 202] [Article Influence: 28.0] [Reference Citation Analysis]
434 Paul S, Moreau AC, Del Tedesco E, Rinaudo M, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X. Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1288-1295. [PMID: 24831559 DOI: 10.1097/mib.0000000000000037] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 11.0] [Reference Citation Analysis]
435 Bryant R, Sandborn W, Travis S. Introducing Vedolizumab to Clinical Practice: Who, When, and How? Journal of Crohn's and Colitis 2015;9:356-66. [DOI: 10.1093/ecco-jcc/jjv033] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
436 Ho EY, Cominelli F, Katz J. Ulcerative Colitis: What is the Optimal Treatment Goal and How Do We Achieve It? Curr Treat Options Gastroenterol. 2015;13:130-142. [PMID: 25619458 DOI: 10.1007/s11938-014-0044-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
437 Christophorou D, Funakoshi N, Duny Y, Valats J, Bismuth M, Pineton De Chambrun G, Daures J, Blanc P. Systematic review with meta-analysis: infliximab and immunosuppressant therapy vs. infliximab alone for active ulcerative colitis. Aliment Pharmacol Ther 2015;41:603-12. [DOI: 10.1111/apt.13102] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
438 Brand S. Für jedes Stadium und Befallsmuster die passende Therapie wählen. MMW - Fortschritte der Medizin 2015;157:45-50. [DOI: 10.1007/s15006-015-2648-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
439 Ferrer Márquez M, Hernández Martínez Á, Reina Duarte Á, Rosado Cobián R. Current Status of the Treatment of Fulminant Colitis. Cir Esp 2015;93:276-82. [PMID: 25649534 DOI: 10.1016/j.ciresp.2014.09.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
440 Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn WJ, Peyrin-Biroulet L. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. Dig Liver Dis. 2015;47:356-364. [PMID: 25661014 DOI: 10.1016/j.dld.2015.01.148] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
441 Park KT, Crandall WV, Fridge J, Leibowitz IH, Tsou M, Dykes DM, Hoffenberg EJ, Kappelman MD, Colletti RB. Implementable strategies and exploratory considerations to reduce costs associated with anti-TNF therapy in inflammatory bowel disease. Inflamm Bowel Dis 2014;20:946-51. [PMID: 24451222 DOI: 10.1097/01.MIB.0000441349.40193.aa] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
442 Ha C, Mathur J, Kornbluth A. Anti-TNF levels and anti-drug antibodies, immunosuppressants and clinical outcomes in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:497-505. [PMID: 25600263 DOI: 10.1586/17474124.2015.983079] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
443 Narula N, Jharap B, Colombel J. Management of Severe Ulcerative Colitis. Curr Treat Options Gastro 2015;13:59-76. [DOI: 10.1007/s11938-014-0036-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
444 Thorlund K, Druyts E, Toor K, Jansen JP, Mills EJ. Incorporating alternative design clinical trials in network meta-analyses. Clin Epidemiol 2015;7:29-35. [PMID: 25565891 DOI: 10.2147/CLEP.S70853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
445 Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015;11:63-73. [PMID: 25609972 DOI: 10.2147/TCRM.S55506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
446 Rossi RE, Parisi I, Despott EJ, Burroughs AK, O'Beirne J, Conte D, Hamilton MI, Murray CD. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management. World J Gastroenterol 2014; 20(46): 17352-17359 [PMID: 25516646 DOI: 10.3748/wjg.v20.i46.17352] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
447 Dubé PE, Punit S, Polk DB. Redeeming an old foe: protective as well as pathophysiological roles for tumor necrosis factor in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2015;308:G161-70. [PMID: 25477373 DOI: 10.1152/ajpgi.00142.2014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
448 Sales-Campos H, Basso PJ, Alves VB, Fonseca MT, Bonfá G, Nardini V, Cardoso CR. Classical and recent advances in the treatment of inflammatory bowel diseases. Braz J Med Biol Res. 2015;48:96-107. [PMID: 25466162 DOI: 10.1590/1414-431x20143774] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
449 Vande Casteele N, Feagan BG, Gils A, Vermeire S, Khanna R, Sandborn WJ, Levesque BG. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep. 2014;16:378. [PMID: 24595615 DOI: 10.1007/s11894-014-0378-0] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 9.3] [Reference Citation Analysis]
450 Herrlinger KR, Stange EF, Fellermann K. Therapeutic peptides in inflammatory bowel disease. Expert Opin Biol Ther 2014;14:455-66. [PMID: 24450849 DOI: 10.1517/14712598.2014.880109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
451 De Felice KM, Novotna M, Enders FT, Faubion WA, Tremaine WJ, Kantarci OH, Raffals LE. Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients. Aliment Pharmacol Ther 2015;41:99-107. [PMID: 25348720 DOI: 10.1111/apt.12997] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
452 Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) 2015;3:103-9. [PMID: 25344680 DOI: 10.1093/gastro/gou070] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
453 Odes S, Greenberg D. A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. Clinicoecon Outcomes Res 2014;6:431-43. [PMID: 25336980 DOI: 10.2147/CEOR.S39212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
454 Seo GS, Chae SC. Biological therapy for ulcerative colitis: An update. World J Gastroenterol 2014; 20(37): 13234-13238 [PMID: 25309060 DOI: 10.3748/wjg.v20.i37.13234] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
455 Schulze H, Esters P, Dignass A. Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation. Aliment Pharmacol Ther 2014;40:991-1008. [PMID: 25200000 DOI: 10.1111/apt.12949] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
456 Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89:1553-1563. [PMID: 25199861 DOI: 10.1016/j.mayocp.2014.07.002] [Cited by in Crossref: 127] [Cited by in F6Publishing: 134] [Article Influence: 15.9] [Reference Citation Analysis]
457 Feuerstein JD, Cheifetz AS. Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy). Gastroenterology Clinics of North America 2014;43:543-63. [DOI: 10.1016/j.gtc.2014.05.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
458 Lin K, Mahadevan U. Pharmacokinetics of Biologics and the Role of Therapeutic Monitoring. Gastroenterology Clinics of North America 2014;43:565-79. [DOI: 10.1016/j.gtc.2014.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
459 Samaan MA, Bagi P, Vande Casteele N, D’haens GR, Levesque BG. An Update on Anti-TNF Agents in Ulcerative Colitis. Gastroenterology Clinics of North America 2014;43:479-94. [DOI: 10.1016/j.gtc.2014.05.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
460 Daperno M, Comberlato M, Bossa F, Biancone L, Bonanomi AG, Cassinotti A, Cosintino R, Lombardi G, Mangiarotti R, Papa A, Pica R, Rizzello F, D'Incà R, Orlando A. Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis 2014;46:969-73. [PMID: 25154049 DOI: 10.1016/j.dld.2014.07.010] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
461 Khan NH, Almukhtar RM. Editorial: Early corticosteroids in ulcerative colitis--authors' reply. Aliment Pharmacol Ther 2014;40:728. [PMID: 25123385 DOI: 10.1111/apt.12898] [Reference Citation Analysis]
462 Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015; 148:37-51.e1. [PMID: 25127678 DOI: 10.1053/j.gastro.2014.08.003] [Cited by in Crossref: 142] [Cited by in F6Publishing: 139] [Article Influence: 17.8] [Reference Citation Analysis]
463 Renna S, Cottone M, Orlando A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9675-9690 [PMID: 25110407 DOI: 10.3748/wjg.v20.i29.9675] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
464 Wolf D, D’Haens G, Sandborn WJ, Colombel JF, Van Assche G, Robinson AM, Lazar A, Zhou Q, Petersson J, Thakkar RB. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014;40:486-497. [PMID: 25041859 DOI: 10.1111/apt.12863] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
465 Aceituno M, Zabana Y, Esteve M. [Treatment of severe ulcerative colitis flares]. Gastroenterol Hepatol 2014;37:471-9. [PMID: 25015428 DOI: 10.1016/j.gastrohep.2014.05.005] [Reference Citation Analysis]
466 Horst S, Kane S. The use of biologic agents in pregnancy and breastfeeding. Gastroenterol Clin North Am 2014;43:495-508. [PMID: 25110255 DOI: 10.1016/j.gtc.2014.05.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
467 Armuzzi A, Felice C. Etrolizumab in moderate-to-severe ulcerative colitis. The Lancet 2014;384:285-6. [DOI: 10.1016/s0140-6736(14)60529-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
468 Ślebioda TJ, Kmieć Z. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediators Inflamm 2014;2014:325129. [PMID: 25045210 DOI: 10.1155/2014/325129] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 6.9] [Reference Citation Analysis]
469 Dulai PS, Siegel CA, Peyrin-Biroulet L. Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD. Gastroenterol Clin North Am 2014;43:441-56. [PMID: 25110252 DOI: 10.1016/j.gtc.2014.05.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
470 Bezzio C, Furfaro F, de Franchis R, Maconi G, Asthana AK, Ardizzone S. Ulcerative colitis: current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy 2014;15:1659-70. [DOI: 10.1517/14656566.2014.925445] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
471 Cohen LB, Nanau RM, Delzor F, Neuman MG. Biologic therapies in inflammatory bowel disease. Translational Research 2014;163:533-56. [DOI: 10.1016/j.trsl.2014.01.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
472 Paine ER. Colonoscopic evaluation in ulcerative colitis. Gastroenterol Rep (Oxf). 2014;2:161-168. [PMID: 24879406 DOI: 10.1093/gastro/gou028] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
473 Gecse KB, Lakatos PL. Ulcerative proctitis: an update on the pharmacotherapy and management. Expert Opinion on Pharmacotherapy 2014;15:1565-73. [DOI: 10.1517/14656566.2014.920322] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
474 Pagnini C, Menasci F, Festa S, Rizzatti G, Fave GD. “Mucosal healing” in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol 2014; 5(2): 54-62 [PMID: 24891976 DOI: 10.4291/wjgp.v5.i2.54] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
475 Kawalec P, Mikrut A, Łopuch S. Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis: Biological therapy for ulcerative colitis. J Gastroenterol Hepatol 2014;29:1159-70. [DOI: 10.1111/jgh.12563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
476 Marchioni Beery R, Kane S. Current approaches to the management of new-onset ulcerative colitis. Clin Exp Gastroenterol. 2014;7:111-132. [PMID: 24872716 DOI: 10.2147/ceg.s35942] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
477 Chapman CG, Rubin DT. The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am 2014;24:353-65. [PMID: 24975527 DOI: 10.1016/j.giec.2014.03.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
478 Rietdijk ST, D'Haens GR. Vedolizumab for the treatment of ulcerative colitis. Expert Rev Clin Pharmacol 2014;7:423-30. [PMID: 24802046 DOI: 10.1586/17512433.2014.911084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
479 Timlin H, Bingham CO 3rd. Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis. Expert Opin Biol Ther 2014;14:893-904. [PMID: 24720727 DOI: 10.1517/14712598.2014.900536] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
480 Bettenworth D, Rieder F. Medical therapy of stricturing Crohn’s disease: what the gut can learn from other organs - a systematic review. Fibrogenesis Tissue Repair. 2014;7:5. [PMID: 24678903 DOI: 10.1186/1755-1536-7-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
481 Zenlea T, Peppercorn MA. Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol 2014; 20(12): 3146-3152 [PMID: 24696600 DOI: 10.3748/wjg.v20.i12.3146] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
482 Altwegg R, Vincent T. TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease. Mediators Inflamm 2014;2014:172821. [PMID: 24757282 DOI: 10.1155/2014/172821] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
483 Schreiber S, Bachmann O. Neue Biologika für die Behandlung chronisch-entzündlicher Darmerkrankungen. Internist 2014;55:367-76. [DOI: 10.1007/s00108-013-3415-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
484 Löwenberg M, de Boer NKh, Hoentjen F. Golimumab for the treatment of ulcerative colitis. Clin Exp Gastroenterol 2014;7:53-9. [PMID: 24648749 DOI: 10.2147/CEG.S48741] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
485 Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2014;12:103-17. [PMID: 24395615 DOI: 10.1007/s11938-013-0008-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
486 Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39:660-671. [PMID: 24506179 DOI: 10.1111/apt.12644] [Cited by in Crossref: 113] [Cited by in F6Publishing: 106] [Article Influence: 14.1] [Reference Citation Analysis]
487 Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther. 2014;14:583-600. [PMID: 24502344 DOI: 10.1517/14712598.2014.885945] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
488 McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014;8:223-40. [PMID: 24490595 DOI: 10.1586/17474124.2014.881715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
489 Lobatón T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:579-594. [PMID: 24479980 DOI: 10.1111/apt.12639] [Cited by in Crossref: 130] [Cited by in F6Publishing: 116] [Article Influence: 16.3] [Reference Citation Analysis]
490 Lv R, Qiao W, Wu Z, Wang Y, Dai S, Liu Q, Zheng X. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One. 2014;9:e86692. [PMID: 24475168 DOI: 10.1371/journal.pone.0086692] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
491 Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:447-58. [PMID: 24444171 DOI: 10.1111/apt.12624] [Cited by in Crossref: 113] [Cited by in F6Publishing: 104] [Article Influence: 14.1] [Reference Citation Analysis]
492 Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol 2014; 20(1): 64-77 [PMID: 24415859 DOI: 10.3748/wjg.v20.i1.64] [Cited by in CrossRef: 93] [Cited by in F6Publishing: 88] [Article Influence: 11.6] [Reference Citation Analysis]
493 Danese S, Peyrin-biroulet L. Enriching the therapeutic armamentarium for IBD. Nat Rev Gastroenterol Hepatol 2014;11:84-6. [DOI: 10.1038/nrgastro.2013.246] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
494 Hanauer SB. Still in pursuit. Gastroenterology 2014;146:13-5. [PMID: 24287301 DOI: 10.1053/j.gastro.2013.11.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
495 Freeman HJ. Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab. Ther Clin Risk Manag. 2013;9:451-456. [PMID: 24235838 DOI: 10.2147/TCRM.S38852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
496 Vaughn BP, Moss AC. Novel treatment options for ulcerative colitis. Clin Investig (Lond) 2013;3:1057-69. [PMID: 24533177 DOI: 10.4155/cli.13.97] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
497 Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014;7:6-19. [PMID: 24084775 DOI: 10.1038/mi.2013.73] [Cited by in Crossref: 192] [Cited by in F6Publishing: 201] [Article Influence: 21.3] [Reference Citation Analysis]
498 Danese S. Golimumab in ulcerative colitis: a 'ménage à trois' of drugs. Nat Rev Gastroenterol Hepatol 2013;10:511-2. [DOI: 10.1038/nrgastro.2013.142] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
499 Smith K. Golimumab shows promise in treatment of active ulcerative colitis. Nat Rev Gastroenterol Hepatol 2013;10:386-386. [DOI: 10.1038/nrgastro.2013.108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
500 Morrow T, Felcone LH. Defining the difference: What Makes Biologics Unique. Biotechnol Healthc. 2004;1:24-29. [PMID: 23393437 DOI: 10.1177/2050640615590302] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 8.6] [Reference Citation Analysis]